

















































time	on	 the	 existence	of	 LHON	associated	with	 peculiar	 combinations	 of	 individually	 non-
pathogenic	missense	mtDNA	variants,	affecting	the	MT-ND4,	MT-ND4L	and	MT-ND6	subunit	











to	 final	 validation.	 Our	 study	 conclusively	 shows	 that	 even	 in	 the	 absence	 of	 a	 clearly	
established	 LHON	 primary	 mutation,	 unprecedented	 combinations	 of	 missense	 mtDNA	
variants,	 individually	 known	 as	 polymorphisms,	 may	 lead	 to	 reduced	 OXPHOS	 efficiency	
sufficient	to	trigger	LHON.	
With	 this	 complexity	 in	mind,	mtDNA	genetic	 variation	 itself	may	play	 a	modifying	 role	 in	
LHON.	 Many	 studies	 reported	 the	 association	 of	 LHON	 and	 a	 specific	 mitochondrial	
haplogroup	classified	as	J.	Here	we	present	the	largest	sequence	survey	of	the	entire	mtDNA	
ever	 performed	 assessing	 119	 independent	 probands	 from	 all	 Europe	 carrying	 the	
m.14484T>C/MT-ND6	mutation.	Besides	the	occasional	finding	of	double	mutants,	we	confirm	
the	 association	with	 the	 haplogroup	 J	 root,	 but	 not	 with	 its	more	 recent	 sub-clades.	 The	
phylogenetic	 analysis	 suggests	 a	 possible	 double	 role	 of	 this	 haplogroup:	 it	 may	 act	 as	
predisposing	 factor	 to	 mutagenesis	 at	 m.14484T	 position,	 or	 preserving	 the	 pathogenic	
	mutation	 during	 evolution.	 On	 the	 clinical	 ground,	 the	 penetrance	 of	 LHON	 due	 to	




neuropathy	 similar	 to	 LHON,	 caused	by	mutations	 in	 the	OPA1	gene,	which	encodes	 for	a	
protein	 essential	 for	 mitochondrial	 fusion	 and	 mitochondrial	 homeostasis.	 Our	 results	
indicated	that	the	relationship	of	DOA	with	mtDNA	genetic	variation	is	complex:	no	specific	
haplogroups	 resulted	 strongly	 associated	 with	 DOA,	 neither	 clearly	 modified	 its	 clinical	










































































they	 are	 also	 involved	 in	 programmed	 cell	 death,	 calcium	 homeostasis	 and	 several	
biosynthetic	pathways.	They	are	wrapped	by	two	membranes,	they	have	their	own	genome,	
an	 independent	 protein	 synthesis	 apparatus,	 and	 can	 change	 their	 shape	 to	 adapt	 to	 the	
different	metabolic	needs	of	the	cell,	from	discrete	isolated	organelles	to	a	large	network.	
Their	origin,	according	to	the	endosymbiotic	theory,	was	due	to	the	increasingly	oxygen-rich	
atmosphere	 and	 the	 primordial	 eukaryotic	 cell,	 unable	 to	 metabolize	 oxygen,	 acquired	
bacteria	much	better	adapted	to	oxygen	(Sagan,	1967;	DiMauro	et	al.,	2013).	
The	 mitochondrial	 genome	 (mtDNA)	 is	 present	 in	 multiple	 copies	 and	 codes	 for	 a	 few	
fundamental	protein	components	of	the	oxidative	phosphorylation	(OXPHOS)	(Anderson	et	
al.,	1981).	
The	 mitochondrial	 double-membrane	 is	 composed	 by	 the	 outer	 (OM)	 and	 inner	 (IM)	
membranes,	this	latter	separating	the	inner	membrane	space	(IMS)	from	the	internal	matrix.	
The	OM	has	similar	composition	to	the	cell	membrane;	many	transport	channels	(porin)	are	
present	and	make	 the	OM	permeable	 to	molecules	of	5000	dalton	or	 less	 (ions	and	 small	
proteins).	 Differently,	 the	 IM	 contains	 high	 levels	 of	 cardiolipin,	 making	 it	 especially	
impermeable	to	ions,	and	selective	transport	proteins	are	needed	to	transport	the	molecules	
necessary	 to	 matrix	 enzymes	 or	 their	 metabolites.	 This	 membrane	 is	 fundamental	 for	
maintenance	 of	 an	 electrochemical	 gradient	 between	 the	 matrix	 and	 the	 IMS	 (Frey	 and	
Mannella,	2000).	The	IM	is	also	organized	in	cristae,	which	can	shift	from	tubular	to	lamellar	
structures,	 depending	 on	 the	 conformational	 state	 (Frey	 and	Mannella,	 2000).	 All	 cristae	
connect	to	the	inner	boundary	membrane	via	a	tubular	structure,	named	crista	junctions,	that	
limits	 diffusion	 between	 the	 intracristal	 space	 and	 the	 intermembrane	 space	 (Frey	 and	
Mannella,	 2000;	 Rampelt	 et	 al.,	 2017).	 Cristae	 are	 the	 specialized	 compartment	 for	 the	
respiratory	chain	complexes	and	the	ATP	synthase	(Rampelt	et	al.,	2017).	
The	fundamental	mitochondrial	function	is	energy	conservation,	in	the	form	of	ATP	molecule,	
synthetized	 by	 the	 OXPHOS	 metabolism.	 Furthermore,	 other	 pathways	 take	 place	 in	










OXPHOS	 is	 the	 final	 step	 of	 cellular	 respiration	 and	 is	 a	 two-phases	 biochemical	 process:	
electron	transport	chain,	with	NADH	and	FADH2	redox	to	generate	a	proton	gradient,	and	ATP	










mobile	 electron	 carriers,	 ubiquinone	 (CoQ)	 and	 cytochrome	 c	 (cyt	 c),	 they	 make	 up	 the	













via	 iron/sulphur	 clusters	 to	 CoQ,	 reduced	 to	 CoQH2	 (Fiedorczuk	 et	 al.,	 2016),	 with	 the	
simultaneous	translocation	of	four	protons	across	the	IM	into	the	inner	membrane	space.	
CII	is	formed	by	four	subunits,	completely	encoded	by	the	nucleus,	and	catalyzes	the	oxidation	













part	 to	 the	 membrane-bound	 portion	 (F0)	 of	 the	 complex,	 and	 about	 13	 other	 subunits	
encoded	by	nDNA	(Abrahams	et	al.,	1994).	Protons	from	the	intermembrane	space	enter	CV	
through	the	F0	complex	leading	to	the	rotation	of	the	catalytic	complex.	The	rotational	energy	
of	 the	motor	 is	 transmitted	 to	 the	catalytic	domain	by	 the	central	 stalk,	which	 is	attached	
directly	to	the	rotary	motor,	and	then	used	for	ATP	synthesis	(Walker,	2013).	ATP	formation	







discrete	mitochondria	merge,	 uniting	 and	mixing	 their	 content.	 Opposite,	 during	 fission	 a	
single	mitochondrion	splits	into	two	organelles.	Continuous	rounds	of	fusion	and	fission	are	



















the	 two	WD40-containing	 adaptors	 (Griffin	 et	 al.,	 2005;	Wells	 et	 al.,	 2007).	Moreover,	 in	
mammals	three	other	receptor	proteins	involved	in	fission	events	are	reported:	Mff,	MiD49	
and	MiD51	(Losón	et	al.,	2013;	Otera	et	al.,	2005).	Mitochondrial	fission	plays	a	key	role	in	




efficiency	 of	 mitophagy,	 suggesting	 that	 fission	 segregates	 mitochondria	 with	 loss	 of	
membrane	potential	(Frank	et	al.,	2012;	Stotland	and	Gottlieb,	2015).	




(Chan,	 2012).	 These	 proteins	 belong	 to	 the	 dynamin-like	 protein	 superfamily	 and	 contain	
GTPase	activity	essential	for	their	functions	(Praefcke	and	McMahon,	2004).	MFN1	is	essential	
to	 induce	 OM	 fusion,	 whereas	 the	 role	 of	MFN2	 is	 less	 defined.	MFN2	 can	 form	 hetero-
oligomers	with	MFN1	and	 is	suggested	to	participate	 in	 later	steps	of	mitochondrial	 fusion	






endoplasmic	 reticulum	 interactions,	 bridging	 the	 two	 organelles	 close	 at	 the	 level	 of	
mitochondrial	 associated	membranes	 (MAMs),	 and	 the	 levels	 of	MFN2	 correlate	with	 the	
oxidative	metabolism	of	skeletal	muscle	(Bach	et	al.,	2003;	de	Brito	and	Scorrano,	2008).	OPA1	
is	essential	for	IM	fusion,	but	it	is	also	involved	in	shaping	the	cristae	morphology,	OXPHOS	









16.6	kb,	 localized	 in	 the	mitochondrial	matrix,	and	 represents	0,5-1%	of	 the	entire	human	
























many	mitochondrial	genomes,	and	 is	 formed	by	stable	 incorporation	of	a	 third,	short	DNA	
strand	known	as	7S	DNA	(Nicholls	and	Minczuk,	2014).	D-loop	is	involved	in	many	function,	






Similar	 to	 bacterial	 chromosomes,	 mitochondrial	 DNA	 is	 organized	 into	 tightly-packed	
nucleoprotein	 complexes	 called	 nucleoids.	 Nucleoids	 are	 found	 associated	 with	 the	 inner	
mitochondrial	 membrane,	 but	 can	 also	 freely	 diffuse	 through	 the	 mitochondrial	 network	
(Albring	et	al.,	1977;	Brown	et	al.,	2011;	Nicholls	and	Minczuk,	2014).	The	most	thoroughly	








asymmetric	modality.	DNA	 synthesis	occurs	 continuously	on	both	 strands	without	Okazaki	













Besides	 the	 replication	 origin	 of	 H-strand,	 D-loop	 contains	 a	 dedicated	 promoter	 for	 the	
transcription	 of	 each	 strand	 of	 mtDNA,	 the	 L-strand	 promoter	 (LSP)	 and	 the	 H-strand	
promoter	 (HSP).	 Transcription	 initiation	 at	 LSP	 or	 HSP	 produces	 near-genome-length	
polycistronic	 transcripts	 that	encompass	all	of	 the	coding	 information	on	each	strand.	The	
primary	transcripts	are	processed	to	release	the	individual	RNA	molecules.	The	steady-state	
levels	 of	 the	 longer	unprocessed	 transcripts	 are	 low	and,	 therefore,	 processing	 is	 likely	 to	
occur	 co-transcriptionally.	 According	 to	 the	 “tRNA	 punctuation	 model”	 model,	 tRNAs	 are	
specifically	recognized	and	cleaved	in	the	polycistronic	transcripts,	thus	leading	to	the	release	
of	tRNAs,	mRNAs,	and	rRNAs	(Anderson	et	al.,	1981;	Ojala	et	al.,	1981),	which	subsequently	
undergo	 further	 maturation	 by,	 for	 example,	 base	 modifications,	 CCA	 addition,	 and	
polyadenylation	 (Hällberg	 and	 Larsson,	 2014).	 In	mammalian	mitochondria,	 the	 5ʹ	 ends	of	
tRNAs	 are	 cleaved	 in	 the	 polycistronic	 transcript	 by	 an	 all-protein	 version	 of	 ribonuclease	











mtDNA	 genetic	 code	 uses	 only	 two	 stop	 codons:	 AGA	 and	 AGG	 (Temperley	 et	 al.,	 2010)	





for	 paternal	 mtDNA	 suggests	 that	 sperm	 mitochondria	 are	 ubiquitinated	 and	 removed	
through	 different	 routes,	 such	 as	 proteosomal,	 lysosomal	 pathways	 or	mitophagy	 (Carelli,	
2015;	Rojansky	et	al.,	2016;	Sato	and	Sato,	2013;	Sutovsky	et	al.,	1999).	Moreover,	autophagy	








or	 heterozygosity.	 Homoplasmy	 occurs	when	 the	 sequence	 of	multiple	mtDNA	 copies	 are	
identical.	 However,	 heteroplasmy	 arises	 when	 a	 variant	 co-exists	 with	 its	 wild-type	
counterpart	 in	 various	 proportions,	 due	 to	 the	 polyploid	 nature	 of	mtDNA	 (Chinnery	 and	
Hudson,	2013;	Payne	et	al.,	2013).	A	heteroplasmic	variant	can	be	inherit	from	mother	to	child	
and	 segregate	 in	 different	 tissue	 with	 varying	 loads,	 according	 to	 the	 ‘mitochondrial	


























the	major	out-of-Africa	haplogroups	M	and	N	 (and	N’s	descendants,	R)	 in	 the	vicinity	of	a	
putative	 “Gulf	 oasis”	 (Richards	 et	 al.,	 2016),	 subsequently	 followed	 by	 haplogroup	 R	
divergence	(Pinhasi	et	al.,	2012).	
In	 the	 last	 decades,	 the	 possible	 role	 of	mtDNA	haplogroups	 in	modulating	mitochondrial	
function	 and	 pathology	 has	 been	massively	 investigated.	 Interestingly,	many	 studies	 have	








association	 of	 mitochondrial	 haplogroups	 has	 been	 noticed	 in	 some	 pathologies,	 such	 as	
psychosis	in	bipolar	disorder	(Frye	et	al.,	2017),	motor	function	in	long-term	HIV-1	infected	
individuals	 (Azar	 et	 al.,	 2017),	 autism	 spectrum	 disorders	 (Chalkia	 et	 al.,	 2017),	
cardiomyopathy	(Shin	et	al.,	2000),	multiple	sclerosis	(Kalman	et	al.,	1999),	Parkinson's	disease	












by	 a	 similar	 involvement	 of	 the	 other	 eye,	 usually	 in	 a	 short	 time	 laps,	 associated	 with	
dyschromatopsia	(Carelli	et	al.,	2004).	In	the	acute	phase,	axonal	loss	in	the	papillo-macular	




















common	 pathogenic	 mutations	 are	 m.11778G>A/MT-ND4,	 m.3460G>A/MT-ND1,	 and	
m.14484T>C/MT-ND6,	characterizing	about	90%	of	LHON	cases	(Howell	et	al.,	1991;	Mackey	
and	Howell,	1992;	Wallace	et	al.,	1988;	Yu-Wai-Man	et	al.,	2011).	These	“primary”	pathogenic	
mutations	 are	 usually	 established	 as	 homoplasmic	 over	 multiple	 generations	 in	 LHON	
maternal	lineages.	However,	two	further	features	remain	peculiar	in	LHON,	i.e.	the	incomplete	
penetrance	and	the	male	prevalence	(Caporali	et	al.,	2017).	Mitochondrial	biogenesis,	which	
is	 boosted	 in	 females	 by	 estrogens	 (Giordano	 et	 al.,	 2011),	 seems	 a	major	 compensatory	
mechanism	 that	 determines	 incomplete	 penetrance	 (Giordano	 et	 al.,	 2014).	 On	 this,	




recurrent	 polymorphic	 mtDNA	 variants	 were	 also	 associated	 with	 LHON	 and	 called	




some	 LHON	 “primary”	 mutations	 with	 a	 specific	 mtDNA	 haplogroup,	 haplogroup	 J,	 as	




















ultimately,	 on	 penetrance	 of	 LHON	 primary	mutations.	 Remarkably,	 the	 role	 of	 the	 same	
mtDNA	variant	may	vary	drastically,	for	example,	from	adaptation	at	high	altitudes,	due	to	an	
environmental	 positive	 selection	 on	 the	 mtDNA	 sequence,	 to	 a	 pathogenic	 potential	
predisposing	 to	 LHON	 in	different	 interacting	environments	 (Caporali	et	al.,	 2017;	 Ji	 et	al.,	
2008).	
Interestingly,	 the	 pathogenic	 role	 of	 the	 m.14484T>C/MT-ND6	 mutation	 was	 initially	 not	
recognized	because	of	the	low	phylogenetic	conservation	of	the	affected	amino	acid	(Howell	
et	al.,	1991;	Mackey	and	Howell,	1992).	Remarkably,	the	m.14484T>C/MT-ND6	change	found	




modulators	 of	 penetrance,	 such	 as	 combinations	 of	 multiple	 private	 “weak”	 pathogenic	
mutations	or	combination	of	established	LHON	pathogenic	mutations	with	variants,	already	




based	 on	 MR-spectroscopy	 were	 unable	 to	 detect	 differences	 between	 LHON	 patients	
carrying	the	m.11778G>A/MT-ND4	mutation	associated	or	not	with	the	mtDNA	haplogroup	J	















common	 amongst	 hereditary	 optic	 neuropathies,	 with	 an	 estimated	 disease	 prevalence	
varying	 from	 1:10,000	 to	 1:30,000	 (Lenaers	 et	 al.,	 2012).	 In	 year	 2000,	 two	 independent	
groups	identified	pathogenic	mutations	in	the	OPA1	gene	as	causative	for	DOA	(Alexander	et	
al.,	2000;	Delettre	et	al.,	2000).	Nowadays,	about	70%	of	DOA	families	have	been	linked	to	
OPA1	mutations	 and	more	 than	 350	pathogenic	mutations	 have	 been	 submitted	 to	OPA1	
databases,	spread	throughout	the	protein	(Ferré	et	al.,	2015;	La	Morgia	et	al.,	2014b).	The	
50%	 of	 DOA	 patients	 carry	 stop-codon,	 frame-shift	 and	 deletion-insertion,	 leading	 to	
incomplete	 transcription	 and	 decreased	 protein	 content,	 with	 haploinsufficiency	 as	 the	
genetic	mechanism.	The	remaining	patients	present	missense	mutations,	which	are	thought	
to	 act	 through	 a	 dominant	 negative	 mechanism.	 In	 2008,	 a	 particular	 group	 of	 missense	
mutations,	 affecting	 the	GTPase	 domain,	 have	 been	 related	 to	 a	 syndromic	 form	of	DOA,	
associated	 with	 sensorineural	 deafness,	 ataxia,	 late-onset	 chronic	 progressive	 external	
ophthalmoplegia	(CPEO)	and	mitochondrial	myopathy	with	cytochrome	c	oxidase	negative.	






(DiMauro	 and	 Schon,	 2008;	 Rouzier	 et	 al.,	 2012).	 Recently,	 other	 phenotypes	 have	 been	
reported	within	the	frame	of	the	DOA	“plus”	syndrome,	including	MS-like	features	(Yu-Wai-
Man	 et	 al.,	 2016),	 Behr-like	 spastic	 paraparesis	 (Marelli	 et	 al.,	 2011),	 Parkinsonism	 and	
dementia	(Carelli	et	al.,	2015)	and	cases	with	absent	or	very	mild	ocular	phenotype	(Milone	et	
al.,	2009),	thus	expanding	the	spectrum	of	OPA1	spectrum.	
As	 LHON,	 DOA	 is	 a	 hereditary	 neurodegenerative	 disorder,	 characterized	 by	 a	 tissue	








visual	 loss,	 and	 as	 in	 LHON,	 DOA	 is	 usually	 symmetrical,	 associated	 with	 centrocaecal	









histopathology	of	 LHON	 (Kjer	 et	 al.,	 1983).	Analysis	 of	 the	 retinal	 nerve	 fiber	 layer	 (RNFL)	
thickness	in	DOA	patients	with	optical	coherence	tomography	(OCT),	a	non-invasive	technique	
used	to	obtain	high-resolution	images,	revealed	generalized	loss	of	fibers,	typically	prevalent	
on	 the	 temporal	 sector,	 with	 a	 smaller	 average	 optic	 disk	 size	 compared	 to	 a	 control	
population	(Barboni	et	al.,	2011,	2014;	Milea	et	al.,	2010).	
Due	to	the	variable	clinical	severity	and	incomplete	penetrance	observed	in	DOA,	similar	to	




















The	 two	 most	 common	 inherited	 optic	 neuropathies	 due	 to	 mitochondrial	 dysfunction,	
Leber’s	Hereditary	Optic	Neuropathy	(LHON)	and	Dominant	Optic	Atrophy	(DOA),	are	both	
characterized	by	an	incomplete	penetrance	and	variable	clinical	severity,	and	in	LHON	there	










The	 first	aim	of	 this	 study	 is	 to	determine	 the	molecular	basis	of	optic	neuropathy	 in	 four	
families,	negative	for	the	common	LHON	pathogenic	mutations,	but	still	characterized	by	a	
clinical	 phenotype	 undistinguishable	 from	 LHON,	 which	 is	 maternally	 inherited	 at	 low	
penetrance.	We	will	carry	out	the	sequence	of	the	entire	mitochondrial	genome	in	each	of	the	
four	 probands	 and	 perform	 confirmatory	 functional	 studies	 by	 assessing	 mitochondrial	
bioenergetics,	 taking	 advantage	 of	 the	 cybrids	 cell	 model	 to	 isolate	 the	 mitogenome	
contribution	to	the	pathogenesis.	














carrying	 OPA1	mutations.	 It	 is	 well	 established	 that	 DOA	 patients	 present	 a	 wide	 clinical	
variability	between	and	within	families,	without	a	clear	genotype-phenotype	correlation	with	























We	 observed	 three	 multigenerational	 pedigrees	 (Families	 1a,	 b,	 and	 c	 in	 Figure	 4)	 with	
multiple	affected	individuals	fitting	the	clinical	diagnosis	of	LHON	and	with	a	clear	maternal	
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Taken	 together	 these	 data	 indicate	 the	 occurrence	 of	 an	 activated	 compensatory	
mitochondrial	 biogenesis,	 most	 likely	 due	 to	 a	 compensatory	 response	 caused	 by	 a	 mild	
mitochondrial	defect,	as	previously	reported	(Giordano	et	al.,	2014;	Iommarini	et	al.,	2012).	
	
	 CI	 CII+III	 CIII	 CIV	
Controls	(mean	±	SD)	 31.7±20.0	 20.3±18.5	 197.94±119.8	 54.6±23.6	
Family	1a	IV:1	 48.10	 29.32	 202.63	 85.23	











SDH	staining	of	skeletal	muscle	biopsies	 from	 individuals	 IV:1	 from	Family	1a	 (a),	V:6	 from	






D.	 The	 evaluation	 of	 citrate	 synthase	 activity,	 presented	 as	 scatter	 plot	 with	mean	 ±	 SD,	
parallels	again	the	results	observed	in	C,	with	an	increased	mean	value	in	the	LHON	samples.	





Sequencing	 of	 the	 entire	 mitochondrial	 genome	 (mtDNA)	 from	 each	 of	 the	 probands	
independently	ascertained	for	Families	1a,	1b	and	1c	revealed	the	same	identical	sequence,	
indicating	 that	 they	descend	 from	 the	 same	maternal	 ancestor,	 as	also	 suggested	by	 their	
geographical	proximity.	They	all	shared	the	diagnostic	variants	for	haplogroup	K1a	and	the	
following	 private	mutations:	 non-coding	m.2281A>G/MT-RNR2	 and	m.16129G>A/MT-HV1;	
synonymous	 m.6137T>C/MT-CO1,	 m.6329C>T/MT-CO1,	 m.8994G>A/MT-ATP6,	
m.11038A>G/MT-ND4	and	m.15253A>G/MT-CYB;	 and	missense	m.14258G>A/MT-ND6	and	





















away	from	an	invariant	position	(G141)	and,	 in	primates	 is	contiguous	to	another	 invariant	
position	(D138)	within	a	moderately	conserved	domain	(6	invariant	positions	out	of	21)	(Figure	
7).	The	V31	position	shows	similar	features.	In	eukaryotes	and	mammals,	glycine	is	prevalent	




Complete	mtDNA	sequence	analysis	of	 the	proband	 from	Family	2	showed	all	 the	variants	
diagnostic	 for	 haplogroup	 H5b	 and	 the	 following	 private	 mutations:	 synonymous	
m.10248T>C/MT-ND3;	 missense	 m.9966G>A/MT-CO3,	 m.10680G>A/MT-ND4L,	
m.12033A>G/MT-ND4	 and	 m.14258G>A/MT-ND6.	 Besides	 the	 m.14258G>A/MT-ND6	
nucleotide	 change,	 Family	 2	 also	 harbored	 the	 m.10680G>A/MT-ND4L	 and	 the	
m.12033A>G/MT-ND4	mutations	that	induce	the	amino	acid	changes	p.A71T	in	ND4L	and	the	





7,	Table	2).	Both	variants	were	considered	neutral	 for	 the	protein	 function	by	most	of	 the	
prediction	tools	employed.	
The	 m.14258G>A/MT-ND6	 change,	 found	 in	 both	 Families	 1	 and	 2,	 has	 been	 previously	
reported	according	to	Mitomap	and	HmtDB	in	10	different	haplogroups,	being	diagnostic	for	
haplogroups	U3a1a1	and	H1q3.	Conversely,	the	m.14582A>G/MT-ND6	(Family	1)	variant	has	












































20 SSKPSPIYGGLALIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
19 NMIHPLALGLTLLIQTIFVCL 39 
18 FYSLSPYYSALGLVVVSISGC 38 
20 ASNPSPYFAALGLVLVAGVGC 40 
20 ASNPAPYFAAFGLVVVAGVGC 40 
20 ASNPSPFYAALGLVLAAGAGC 40 
18 VRAKNPVHSVLFFILVFCDTS 38 
38 ILTKNPIVSVLFLILLFGGIS 58 
18 INIDPMKSSFFLIFSLLFSMP 38 
              * 
130 EGSGLIREDLIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
119 ----INMNFMENSLSLNKLYN 135 
119 DGGGVSFADFSGVAVFYSCGV 139 
121 IEFSVVAADSGGVALMYSLGG 141 
120 KEFSVIRADVSGVAMMYSSGG 140 
118 LGSYVMRGDWVGVALMYSC-W 137 
119 TTSL---TETLG-NLLYTYYF 135 
141 SEDFIDFNTAIG-NIMYTIYN 160 
94  ------PTTYSSYLGLSGFYY 108 














20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
19 SSKPSPIYGGVGLIVSGAVGC 39 
20 ALKPSPIYGGLGLIVSGFVGC 40 
20 SSKPSPIYGGLGLIVSGGVGC 40 
21 SSKPSPIYGGLVLIVSGGVGC 41 
21 SSKPSPIYGGLGLIVSGGVGC 41 
21 SSKPSPIYGGLGLIVGGGVGC 41 
21 SSKPSPIYGGLVLIISGAVGC 41 
21 SSKPSPIYGGFGLIVAGGTGC 41 
20 ASKPSPIYGGLSLVLSGGVGC 40 
              * 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGPGLIREDPIGAGALYDYGR 150 
129 KEGGVIREDSLGVASLYNKAS 149 
129 DDVGVMLEGGIGVAAMYSCAT 149 
130 DEVGLIREDSMGVAALYSYGS 150 
131 GDSGAFSEEIMGAAALYSYGA 151 
131 GDSGFFSEEAMGIAALYSYGT 151 
131 GGSGVFSEEATGIAALYSYGV 151 
131 GDSGFFSEEAMGIAALYSYGT 151 
131 GDSGFFSEEAMGIAALYSYGT 151 
121 GGVEVLGGDYNGVSLLSACGG 141 










20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIISGAVGC 40 
20 SSKPSPIYGGLVLIISGAVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLVVSGVVGC 40 
19 SSKPSPIYGGVGLIVSGAVGC 39 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGPGLIREDPIGAGALYDYGR 150 
130 EGPGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDSIGAGALYDYGR 150 
129 KEGGVIREDSLGVASLYNKAS 149 
	
	
















60 PIAMLVFAACETAVGLALLVS 80 
60 PIAMLVFAACEAAVGLALLVS 80 
60 SMMFLTFSVCEGALGLSILVS 80 
59 NLLLLTLSACEASIGLSLMVA 79 
60 PMLMLAFSACEASAGLALLVA 80 
60 PMLLLAFSACEASAGLALLVA 80 
60 LYIMLPFAAPEAATGLSLNSD 80 
60 ALLVLTVAAAESAIGLAIFVI 80 
54 AIYIIVVAGAESAIGLGILVA 74 
45 FFYFMCFSVISSILGMVVMVG 65 
              * 
415 QWGSLTHHINSMKPSFTRENT 435 
415 QWGSLTHHINNMKPSFTRENT 435 
402 QHGKLFSGVYSFSSGKIREYL 422 
414 QQGTPTNNINNISLSFSREHL 434 
415 QRGPLPQHMLALPPSYTREHL 435 
415 QRGSIPEHITNLSPSHTREHL 435 
414 QRGMTPEHLNAINPTHTREHT 434 
411 VSGLKPDFLHKFSDLNGREVF 431 
407 AFGFSKFFEENIGDVTKREFF 427 
372 LMGKGYHNFNTWNVGFSAPLV 392 














60 PIAMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PILLLVFAACEAAVGLALLVT 80 
60 PIT-LVFAACEAAVGLALLVK 79 
60 PIILLVFAACEAAVGLALLVM 80 
60 PIILLVFAACERALGLSLLVM 80 
60 PIILLVFAACEAALGLSLLVM 80 
60 PIILLVFAACEAAIGLALLVM 80 
60 PIILLVFAACEAALGLSLLVM 80 
60 PIILLVFAACEAALGLSLLVM 80 
60 PLILLVFSACEAGVGLALLVK 80 
              * 
415 QWGSLTHHINNMKPSFTRENT 435 
415 QWGSLTHHINSMKPSFTRENT 435 
415 QRGKLTYHSHNLNPSFTRENT 435 
415 QRGKLTNHMINLQPSHTRELT 435 
415 QRGKFTYHTNNISPTFTRENT 435 
415 QRGKYTHHINSIKPSFTRENA 435 
415 QRGKYTYHINNISPSFTRENA 435 
415 QRGKHTHHINNITPSFTREHA 435 
415 QRGKYTYHIKNIKPSFTRENA 435 
415 QRGKYTHHIKNINPSFTRENA 435 
415 QRGKLTSHSLSINPSFTREHM 435 










60 PIAMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLAS 80 
60 PITMLVFAACEAAVGLALLAS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PVVLLVFAACEAAVGLALLVS 80 
60 PILLLVFAACEAAVGLALLVT 80 
415 QWGSLTHHINNMKPSFTRENT 435 
415 QWGSLTHHINNMKPSFTRENT 435 
415 QWGSLTHHINSMKPSFTRENT 435 
415 QRGTPTHHTNNMKPSFTRENT 435 
415 QRGTPSHHINNMKPSSTRENT 435 
415 QWGPLTHHITNMKPSFTRENI 435 
415 QRGTLTHHIKNMKPSLTRENM 435 




amino	 acids)	 of	m.14582A>G/MT-ND6,	m.14258G>A/MT-ND6,	m.10680G>A/MT-ND4L	 and	










Family	 1,2	 1	 2	 2	
Mutation	 m.14258G>A	 m.14582	A>G	 m.10680	G>A	 m.12033	A>G	
Gene	 MT-ND6	 MT-ND6	 MT-ND4L	 MT-ND4	
AA_change	 p.P139L	 p.V31A	 p.A71T	 p.N425S	
PolyPhen2	 benign	 benign	 benign	 benign	
SIFT	 neutral	 neutral	 neutral	 neutral	
FatHmm	 neutral	 neutral	 neutral	 neutral	
PROVEAN	 neutral	 neutral	 deleterious	 neutral	
MutationAssessor	 neutral_impact	 neutral_impact	 high_impact	 low_impact	
CADD	 deleterious	 neutral	 neutral	 neutral	
PANTHER	 neutral	 neutral	 disease	 neutral	
PhD-SNP	 neutral	 neutral	 disease	 neutral	
MtoolBox	 neutral	 neutral	 neutral	 deleterious	
APOGEE_boost	 N	 N	 N	 N	
GB	 16/32,059	 179/32,059	 14/32,059	 5/32,059	
Frequency	 19/31,735	 188/31,735	 14/31,735	 6/31,735	
Conservation	
Eukaryota	 F	22%	 G	49%	 A	86%	 N	42%	
Vertebrata	 F	32%	 G	69%	 A	97%	 N	54%	
Mammalia		 A	37%	 G	46%	 A	97%	 N	70%	
Local	 63%	 85%	 87%	 77%	
Global	 71%	 71%	 80%	 83%	
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To	 assess	 the	 pathogenic	 potential	 of	 the	 two	peculiar	 combinations	 of	missense	 variants	
found	 in	 Family	 1	 (m.14258G>A/MT-ND6	 and	 m.14582A>G/MT-ND6)	 and	 Family	 2	






the	 mitochondrial	 oxidative	 phosphorylation	 system,	 we	 grew	 cybrids	 in	 a	 glucose-free	
medium	 containing	 galactose;	 under	 these	 conditions,	 the	 rate	 of	 glycolysis	 is	 markedly	
reduced	 and	 cells	 are	 forced	 to	 rely	 on	 oxidative	 phosphorylation	 for	 ATP	 production	
(Robinson	et	al.,	1992).	No	significant	differences	were	found	in	LHON	cell	viability	compared	
to	controls	 (Figure	8A).	Assessment	of	Complex	 I	 redox	activity	displayed	a	non-significant	
reduction	in	LHON	cells	(Figure	8B),	indicating	that	the	combinations	of	variants	did	not	affect	




driven	by	Complex	 I	 substrates	 (malate	and	glutamate),	was	significantly	 reduced	 in	LHON	
cells,	whereas	ATP	synthesis	was	normal	when	driven	by	Complex	 II	 substrates	 (succinate)	
(Figure	8E).	
Although	LHON	mutations	have	been	reported	to	exert	their	pathogenic	role	by	 increasing	
oxidative	 stress	 (Carelli	 et	 al.,	 2004;	 Yu-Wai-Man	 et	 al.,	 2011),	 we	 failed	 to	 reveal	 any	




















Figure	 9.	Production	 of	 superoxide	 anion	 and	 hydrogen	 peroxide	 in	 cybrid	 cell	 lines.	A.	
Mitochondrial	superoxide	anion	production	determined	by	epifluorescence	microscopy	using	













we	 took	 advantage	 of	 the	 recently	 released	 structure	 of	 mammalian	 enzyme	 at	 3.9 Å	
resolution,	 solved	 by	 cryo-electron	microscopy	 (Fiedorczuk	 et	 al.,	 2016).	We	 analyzed	 the	
position	of	amino	acids	affected	by	the	polymorphic	variants,	namely	m.14258G>A/MT-ND6,	
m.14582A>G/MT-ND6,	 m.10680G>A/MT-ND4L	 and	 m.12033A>G/MT-ND4	 (Figure	 10),	 but	
also	 the	 variants	 in	 three	 LHON	 Chinese	 families,	 with	 m.10680G>A/MT-ND4L	 found	 in	












which	 faces	 the	mitochondrial	 matrix.	 Interestingly,	 with	 the	 only	 exception	 of	 the	 latter	
amino	acid	change,	all	 the	other	variants	affect	positions	around	the	putative	E-channel	of	
Complex	I	(Castellana	et	al.,	2015),	suggesting	that	the	mild	functional	defect	found	in	these	












human	 p.V31A,	 m.14582A>G/MT-ND6)	 and	 Ala71	 (corresponding	 to	 human	 p.A71T,	
m.10680G>A/MT-ND4L)	are	shown	as	red-labelled	spheres;	whereas	residues	Glu143/ND1,	
Glu192/ND1,	Glu34/ND4L,	Tyr60/ND6,	the	key	residues	for	the	E-channel	(near	Q	site),	are	












mtDNA	 variants,	 adaptive	 for	 high	 altitude	 in	 Tibet,	 on	 the	 ovine	 Complex	 I	 structure.	
Positioning	of	the	combinations	of	variants	in	three	LHON	Chinese	families	(A-B)	(Yang	et	al.,	
2009;	Zhang	et	al.,	2012;	Zou	et	al.,	2010)	and	the	adaptive	variants	for	high	altitude	in	Tibet	
(C-D)	 (Ji	 et	 al.,	 2012;	 Kang	 et	 al.,	 2013)	 on	 crystallographic	 structure	 of	 ovine	 Complex	 I	
(Fiedorczuk	et	al.,	2016),	using	the	UCSF	Chimera	software.	In	panels	A	and	B,	the	ovine	amino	
acids	 Ala71	 (corresponding	 to	 human	 p.A71T,	 m.10680G>A/MT-ND4L)	 are	 shown	 as	 red	
labelled	spheres,	and	this	variant	is	associated	in	each	families	with	Met65	(corresponding	to	
human	 p.M64V,	 m.14484T>C	 /MT-ND6),	 Ala147	 (corresponding	 to	 human	 p.A147T,	
m.3745G>A/MT-ND1),	 Leu81	 (corresponding	 to	 human	 p.I81T,	 m.3548T>C/MT-ND1)	 or	
Val113	 (corresponding	 to	 human	 p.V113A,	m.3644T>C/MT-ND1),	 shown	 as	 green	 labelled	
spheres.	 In	 panels	 C	 and	 D,	 the	 ovine	 amino	 acids	 Ala147	 (corresponding	 to	 p.A147T,	
m.3745G>A/MT-ND1),	His304	(corresponding	to	human	p.Y139H,	m.4216T>C/MT-ND1)	and	




red,	 respectively.	 The	 variants	 combination	 in	 LHON	 Chinese	 families	 (A-B)	 and	 adaptive	










We	 completely	 sequenced	 mtDNA	 in	 147	 probands,	 affected	 by	 LHON	 carrying	 the	







































H4a1a	 H	 16362	T>C	 13497	A>G	 	
H4a1a1a	 H	 195	T>C	 15172	G>A	 	










H5b4	 H	 16145	G>A	 6620	T>C	
12501	G>A	
	
H6a1a	 H	 	 15784	T>C	 	
H7c1	 H	 16093	T>C	 11533	C>T	 	






H27	 H	 	 	 3368	T>C	
H56	 H	 	 10235	T>C	 	














V10b1	 H	 	 	 	
J1b1a1	 J	 146	T>C	 	 	






















J1b1a1d	 J	 1462	G>A	 	 4659	G>A	
J1b1a1d	 J	 	 	 8557	G>C	















J1c1d	 J	 	 	 	
J1c2	 J	 	 3375	C>T	 	
J1c2b	 J	 	 	 	
J1c2c1	 J	 	 	 	
J1c2e	 J	 194	C>T	 	 	
J1c2j	 J	 	 	 14279	G>A	
J1c2j	 J	 	 	 4184	T>A	
14279	G>A	
J1c3	 J	 182	C>T	 3372	T>C	 	
J1c3a	 J	 	 	 	
J1c3b	 J	 	 10915	T>C	 10609T>C	
J1c3b1a	 J	 	 	 8989	G>A	
J1c3e2	 J	 16325	T>C	 5147	G>A	 6712	A>T	
9957	T>C	











J1c3j	 J	 	 	 	
J1c4	 J	 	 11260	T>C	 	
J1c4	 J	 	 7271	A>G	
13641	T>C	
	















































J2a2c	 J	 	 14569	G>A	 7269	G>A	
J2a2c	 J	 	 	 7269	G>A	
J2b1	 J	 16265	A>T	 6959	C>G	 4824	A>G	
8953	A>G	
15315	C>T	
J2b1a2	 J	 246	T>C	 3348	A>G	 	
J2b1a3	 J	 709	G>A	 13029	C>T	 	
J2b1a3	 J	 709	G>A	 	 8743	G>A	
J2b1a6	 J	 	 8557	A>C	 9025	G>A	
J2b1a6	 J	 	 13194	G>A	 	
J2b1a6	 J	 	 	 	
J2b1b1	 J	 146	T>C	 10124	T>C	 8711	A>G	



















































T2b	 T	 	 3828	A>G	 	
T2b3b	 T	 	 	 	























































U5a1a2b	 U	 16082	C>T	 4023	T>C	
10535	T>C	
4160	T>C	
U5a1c1	 U	 15928	G>A	 	 	
U5b1b1	 U	 16093	T>C	 	 	
K1a1b1	 K	 5583	C>T	 	 	




B2	 other	 	 9254	A>G	
9548	G>A	
7119	G>A	

















L2a1l2	 other	 198	C>T	 7492	C>T	 4136	A>G	
L3e1a	 other	 	 	 	




L3e5a	 other	 3290	T>C	 	 5460	G>A	
8888	T>C	


















Missense	 variant	 in	 coloured	 according	 scoring	 criteria	 described	 in	 the	 “materials	 and	
methods”	as	in	table	6.	
	













of	 the	 strong	 association	 of	 haplogroup	 J	 with	 the	 m.14484T>C/MT-ND6	 mutation,	 we	
dissected	further	haplogroup	J	 into	the	sub-clades.	Of	relevance,	previous	studies	reported	
the	association	with	specific	clades	of	haplogroup	J,	i.e.	J1c	(Carelli	et	al.,	2006;	Hudson	et	al.,	







the	 European	 population	 (χ2test,	 J	 sub-ckades	 p=0.4046,	 J1	 sub-ckades	 p=0.1285,	 J2	 sub-
ckades	p=1.000)	(Figure	13).	
	



















PolyPhen2	 SIFT	 PANTHER	 PhD-SNP	 Mammals	 Local	 Global	 -	 +	
m.3316G>A	 MT-ND1	 p.A4T	 benign	 neutral	 NA	 neutral	 67	 57	 78	 3	 12	
m.3368T>C	 MT-ND1	 p.M21T	 benign	 neutral	 NA	 neutral	 92	 81	 78	 1	 1	
m.3434A>G	 MT-ND1	 p.Y43C	 benign	 neutral	 neutral	 disease	 82	 86	 78	 2	 1	
m.3460G>A	 MT-ND1	 p.A52T	 probably_damaging	 neutral	 neutral	 disease	 97	 86	 78	 1	 2	
m.3523A>G	 MT-ND1	 p.T73A	 benign	 neutral	 neutral	 neutral	 51	 68	 78	 10	 2	
m.3535T>A	 MT-ND1	 p.L77M	 probably_damaging	 neutral	 neutral	 neutral	 95	 57	 78	 2	 9	
m.4123A>G	 MT-ND1	 p.I273V	 benign	 neutral	 neutral	 neutral	 70	 81	 78	 1	 1	
m.4136A>G	 MT-ND1	 p.Y277C	 probably_damaging	 neutral	 disease	 disease	 99	 86	 78	 3	 1	
m.4160T>C	 MT-ND1	 p.L285P	 probably_damaging	 neutral	 disease	 disease	 100	 100	 78	 1	 1	
m.4184T>A	 MT-ND1	 p.F293Y	 probably_damaging	 neutral	 disease	 neutral	 100	 100	 78	 2	 1	
m.4216T>C	 MT-ND1	 p.Y304H	 benign	 neutral	 neutral	 neutral	 62	 67	 78	 6	 11	
m.4561T>C	 MT-ND2	 p.V31A	 benign	 neutral	 neutral	 neutral	 56	 67	 62	 1	 1	
m.4639T>C	 MT-ND2	 p.I57T	 benign	 neutral	 neutral	 neutral	 86	 76	 62	 6	 2	
m.4659G>A	 MT-ND2	 p.A64T	 benign	 neutral	 disease	 disease	 93	 76	 62	 1	 2	
m.4695T>C	 MT-ND2	 p.F76L	 benign	 neutral	 neutral	 neutral	 73	 57	 62	 9	 8	
m.4824A>G	 MT-ND2	 p.T119A	 benign	 neutral	 disease	 neutral	 94	 81	 62	 1	 1	
m.5460G>A	 MT-ND2	 p.A331T	 benign	 neutral	 neutral	 neutral	 46	 48	 62	 22	 7	






m.6712A>T	 MT-CO1	 p.Y270F	 probably_damaging	 neutral	 disease	 disease	 100	 100	 95	 1	 1	
m.7080T>C	 MT-CO1	 p.F393L	 probably_damaging	 neutral	 neutral	 disease	 100	 100	 95	 1	 2	
m.7119G>A	 MT-CO1	 p.D406N	 benign	 neutral	 neutral	 neutral	 83	 90	 95	 4	 1	
m.7257A>G	 MT-CO1	 p.I452V	 benign	 neutral	 neutral	 neutral	 77	 90	 95	 1	 2	
m.7269G>A	 MT-CO1	 p.V456M	 benign	 neutral	 neutral	 neutral	 77	 86	 95	 1	 1	
m.7270T>C	 MT-CO1	 p.V456A	 benign	 deleterious	 neutral	 neutral	 77	 86	 95	 1	 1	
m.7440T>G	 MT-CO1	 p.S513A	 benign	 neutral	 neutral	 neutral	 33	 55	 95	 5	 -	
m.7859G>A	 MT-CO2	 p.D92N	 benign	 neutral	 neutral	 neutral	 75	 95	 89	 3	 1	
m.8400T>C	 MT-ATP8	 p.M12T	 benign	 neutral	 neutral	 neutral	 55	 62	 46	 3	 39	
m.8448T>C	 MT-ATP8	 p.M28T	 benign	 neutral	 neutral	 neutral	 47	 33	 46	 19	 23	
m.8516T>C	 MT-ATP8	 p.W51R	 probably_damaging	 neutral	 disease	 disease	 100	 48	 46	 42	 4	
m.8557G>C	 MT-ATP6	 p.A11P	 possibly_damaging	 neutral	 neutral	 disease	 68	 67	 77	 2	 1	
m.8557G>C	 MT-ATP8	 p.L64F	 probably_damaging	 neutral	 disease	 neutral	 80	 67	 46	 7	 -	
m.8711A>G	 MT-ATP6	 p.N62S	 benign	 neutral	 neutral	 neutral	 83	 67	 77	 1	 3	
m.8743G>A	 MT-ATP6	 p.V73M	 benign	 neutral	 neutral	 neutral	 44	 71	 77	 2	 2	
m.8812A>G	 MT-ATP6	 p.T96A	 probably_damaging	 neutral	 neutral	 neutral	 98	 95	 77	 1	 1	
m.8843T>C	 MT-ATP6	 p.I106T	 benign	 deleterious	 disease	 neutral	 98	 81	 77	 1	 3	
m.8888T>C	 MT-ATP6	 p.I121T	 benign	 neutral	 neutral	 neutral	 71	 76	 77	 1	 1	
m.8953A>G	 MT-ATP6	 p.I143V	 probably_damaging	 neutral	 neutral	 neutral	 85	 86	 77	 3	 1	
m.8989G>A	 MT-ATP6	 p.A155T	 probably_damaging	 neutral	 neutral	 disease	 93	 95	 77	 2	 2	
m.9025G>A	 MT-ATP6	 p.G167S	 probably_damaging	 deleterious	 disease	 disease	 100	 90	 77	 1	 1	
m.9053G>A	 MT-ATP6	 p.S176N	 benign	 neutral	 neutral	 neutral	 58	 76	 77	 1	 23	
m.9055G>A	 MT-ATP6	 p.A177T	 possibly_damaging	 neutral	 disease	 disease	 90	 71	 77	 2	 22	
m.9067A>G	 MT-ATP6	 p.M181V	 benign	 deleterious	 neutral	 neutral	 90	 57	 77	 6	 18	
m.9103T>C	 MT-ATP6	 p.F193L	 benign	 neutral	 disease	 neutral	 93	 62	 77	 18	 6	
m.9137T>C	 MT-ATP6	 p.I204T	 benign	 neutral	 NA	 neutral	 66	 86	 77	 1	 7	
m.9327A>G	 MT-CO3	 p.T41A	 benign	 neutral	 neutral	 neutral	 42	 71	 92	 5	 1	
m.9957T>C	 MT-CO3	 p.F251L	 benign	 neutral	 neutral	 disease	 100	 100	 92	 1	 1	
m.10237T>C	 MT-ND3	 p.I60T	 probably_damaging	 neutral	 disease	 disease	 100	 100	 69	 3	 1	
m.10320G>A	 MT-ND3	 p.V88I	 benign	 neutral	 neutral	 neutral	 46	 29	 69	 10	 10	
m.10398A>G	 MT-ND3	 p.T114A	 benign	 neutral	 neutral	 neutral	 81	 92	 69	 1	 -	
m.10609T>C	 MT-ND4L	 p.M47T	 benign	 neutral	 neutral	 neutral	 51	 48	 69	 13	 13	
m.10680G>A	 MT-ND4L	 p.A71T	 benign	 neutral	 disease	 disease	 97	 81	 69	 11	 3	
m.10845C>T	 MT-ND4	 p.T29I	 benign	 neutral	 NA	 neutral	 36	 62	 77	 3	 6	
m.11778G>A	 MT-ND4	 p.R340H	 probably_damaging	 deleterious	 disease	 disease	 100	 90	 77	 2	 2	
m.11969G>A	 MT-ND4	 p.A404T	 benign	 neutral	 disease	 disease	 84	 67	 77	 5	 2	
m.12361A>G	 MT-ND5	 p.T9A	 unknown	 neutral	 NA	 neutral	 59	 26	 68	 -	 6	
m.13105A>G	 MT-ND5	 p.I257V	 benign	 neutral	 neutral	 neutral	 59	 86	 68	 1	 1	
m.13135G>A	 MT-ND5	 p.A267T	 benign	 neutral	 disease	 neutral	 56	 67	 68	 4	 12	
m.13621C>T	 MT-ND5	 p.L429F	 benign	 neutral	 disease	 neutral	 67	 62	 68	 4	 6	
m.13708G>A	 MT-ND5	 p.A458T	 benign	 neutral	 disease	 disease	 44	 67	 68	 1	 7	
m.13712C>T	 MT-ND5	 p.A459V	 benign	 neutral	 neutral	 disease	 46	 62	 68	 2	 6	
m.14258G>A	 MT-ND6	 p.P139L	 benign	 neutral	 neutral	 neutral	 37	 38	 52	 57	 2	
m.14279G>A	 MT-ND6	 p.S132L	 benign	 neutral	 neutral	 neutral	 60	 24	 52	 50	 9	
m.14484T>C	 MT-ND6	 p.M64V	 probably_damaging	 neutral	 neutral	 disease	 58	 95	 52	 1	 1	
m.14564A>G	 MT-ND6	 p.V37A	 benign	 neutral	 neutral	 disease	 70	 67	 52	 1	 2	
m.14582A>G	 MT-ND6	 p.V31A	 benign	 neutral	 neutral	 neutral	 47	 86	 52	 2	 1	
m.14861G>A	 MT-CYB	 p.A39T	 benign	 neutral	 neutral	 neutral	 39	 81	 82	 2	 1	
m.15221G>A	 MT-CYB	 p.D159N	 benign	 neutral	 neutral	 disease	 38	 95	 82	 2	 4	
m.15315C>T	 MT-CYB	 p.A190V	 benign	 neutral	 neutral	 disease	 41	 86	 82	 3	 6	
m.15458T>C	 MT-CYB	 p.S238P	 benign	 neutral	 neutral	 disease	 27	 52	 82	 7	 9	












pathogenic	 mutations	 in	 MT-ND1	 (m.4136A>G,	 m.4160T>C,	 m.4184T>A),	 1	 in	 MT-ND3	
(m.10237T>C),	 1	 in	 MT-ND2	 (m.4659G>A),	 1	 in	 MT-CO1	 (m.6712A>T),	 1	 in	 MT-CO3	
(m.9957T>C),	1	in	MT-ATP8	(m.8516T>C)	and	2	in	MT-ATP6	(m.8989G>A,	m.9025G>A).	







We	 show	 the	 branches	 of	 haplogruops	 J	 and	 T,	 because	 these	 two	 were	 the	 only	 with	
recurrent	haplotypes	(Figures	14).	
A	possibly	ancient	founder	event	is	recognized	on	J1b1a1,	which	spread	in	central	Europe	with	
3	 families	 in	 Italy,	 2	 in	 France	 and	 6	 in	 Germany.	 Other	 founder	 events	 still	 occurring	 on	
haplogroup	 J	 are	noticed	on	 J1c1d,	 J1c2j,	 J1c3e2,	 J1c3f,	 J1c4	and	 J2b1	 clades,	 but	 also	on	
haplogroup	T,	in	particular	on	T1a2,	T2	and	T2c1d1	clades	(Figure	14).	
J	 	C295T	T489C	A10398G!	A12612G	G13708A	C16069T		 LHON	
	 J1	 	C462T	G3010A		 Family	
	 		 J1b	 	G8269A	G16145A	(C16222T)	C16261T		 		
	 		 		 J1b1	 	G5460A	T13879C		 		
	 		 	 		 J1b1a	 	C242T	T2158C	G8557A	G12007A		 		
	 		 	 	 		 J1b1a1	 	T16172C		 		
	 		 	 	 	 		 T789C	G10427A	 Italy	
	 		 	 	 	 		 		 T13743C	 Italy	
	 		 	 	 	 		 	 		 T146C	G657A	 Italy	
	 		 	 	 	 		 T146C	 France	
	 		 	 	 	 		 	 G13135A	 France	
	 		 	 	 	 	 		 T16311C	 Germany	
	 		 	 	 	 	 A7543G	G14861A	T16093C	 Germany	
	 		 	 	 	 	 J1b1a1b	 	T15067C	 	
	 		 	 	 	 		 		 T3535A	T15262C	G15930A	C16256T	C16260T	 Germany	
	 		 	 	 	 	 J1b1a1d	 	G185A	T6345C	A7299G		 Germany	
	 		 	 	 	 	 		 G1462A	G4659A	 Germany	
	 		 	 	 	 	 		 G8587C	h	 Germany	
	 		 J1c	 	(G185A)	(G228A)	T14798C		 	 	
	 		 		 T1284C	C4017T	T5788C	A9425G	G13135A	T15394C	C16114T	A16215G	A16265T	 Turkey	
	 		 	 J1c1	 	T482C	T3394C	 	
	 		 	 		 J1c1d	 	G16213A	 Germany	
	 		 	 		 	 T8383C	G9053A	T10031C	 Germany	
	 		 	 		 	 	 A183G	 Germany	
	 		 	 J1c2	 	A188G		 	 	
	 		 	 		 		 C3375T	 Germany	
	 		 	 		 J1c2b	 	T4454C		 Germany	
	 		 	 		 J1c2c	 	(T146C!)	G10685A	T13281C	A13933G		 UK	
	 		 	 		 J1c2e	 	C16366T		 	 	
	 		 	 		 	 C194T	 Serbia	
	 		 	 		 J1c2j	 	C8727T	T16362C	G16390A	 		
	 		 	 		 	 G14279A	 Italy	






	 		 	 J1c3	 	C13934T		 	
	 		 		 		 	 C182T	T3372C	 Italy	
	 		 		 		 J1c3a	 	G9548A		 	 Italy	
	 		 		 		 J1c3b	 	C15367T		 	 	
	 		 		 		 		 T10609C	T10915C	 UK	
	 		 		 		 		 J1c3b1	 	G5237A	 	
	 		 		 		 	 		 J1c3b1a	 	G6261A		 	
	 		 		 		 	 	 	 G8989A	 UK	
	 		 		 		 J1c3e	 	G16390A		 	 	
	 		 		 		 		 J1c3e2	 	G8865A	 	
	 		 		 		 	 		 G5147A	A6712T	T9957C	T16325C	 France	
	 		 		 		 	 		 C16291T	 Italy	
	 		 		 		 J1c3f	 	T12477C	T16063C	 	
	 		 		 		 		 G709A	C10845T	 	
	 		 		 		 	 		 T16093C	 US	
	 		 		 		 	 		 A2181G	A8458G	 US	
	 		 		 		 J1c3g	 	G9755A	 	
	 		 		 		 		 A188G	T195C	G14364A	T16243C	 Italy	
	 		 		 		 J1c3j	 	A12358G	T16311C!	 Germany	
	 		 		 J1c4	 	A9632G	T12083g	 	
	 		 		 		 T11260C	 Germany	
	 		 		 		 A7271G	T13641C	 Germany	
	 		 		 		 T16189C	 UK	
	 		 		 J1c5	 	A5198G	 	
	 		 		 		 T489C	T4209C	A12819G	C16174T	 France	
	 		 		 J1c6	 	C4025T	 	
	 		 		 		 C182T	 Germany	
	 		 		 J1c9	 	C6887T	 	
	 		 		 		 C189G	T254C	C6602T	T10786C	A12361G	A16343G	 Germany	
	 		 		 J1c10	 	C5024T	 	
	 		 	 		 T195C	C198T	A3358G	T4561C	G12501A	A12648G	C13621T	 Italy	
	 		 J1d	 	T152C!	G7789A	A7963G	 	
	 	 		 J1d1	 	A16300G	 	
	 	 	 		 J1d1a	 	G1007A	A16309G	 	
	 	 	 	 		 J1d1a1	 	T13392C	 	
	 	 	 	 	 		 A8812G	C15430T	T16093C	A16203G	 Italy	
	
T	 	G709A	G1888A	A4917G	G8697A	T10463C	G13368A	G14905A	A15607G	G15928A	C16294T		 		
		 T1	 	C12633a	A16163G	T16189C!		 		
		 		 T1a	 	C16186T		 		
		 	 		 	T152C!		 		
		 	 	 		 T1a1'3	 	T195C!		 		
		 	 	 		 		 T1a1	 	T9899C		 		
		 	 	 		 	 		 T1a1b	 	G10143A	C14281T		 Germany	
		 	 	 		 T1a2	 	G7853A		 		
		 	 	 	 		 A633G	G8994A	A9377G	A10398G	A10876G	A11239G	 Italy	
		 	 	 	 	 		 T204C	 Italy	
		 	 	 	 	 	 		 C8640T	 Italy	
		 	 	 	 	 	 		 T152C	T8516C	C16185T	 Italy	
		 T2	 	A11812G	A14233G	(C16296T)		 		
	 		 A490G	A5378G	T7440G	T12681C	A12819G	G13194A	 Italy	
	 		 		 G3460A	 Italy	
	 		 		 G10680A	 Italy	
	 		 T2b	 	G930A	G5147A	T16304C		 		
	 		 		 A3828G	 Germany	
	 		 		 		 G185A	T16178C	 Germany	
	 		 		 T2b3	 	A10750G		 		
	 		 		 		 T2b3b	 	A13722G		 France	
	 		 		 T2b25	 	G7521A!	C8934T		 		
	 		 	 		 A9067G	T10237C	T16311C	 Germany	
	 	 	 	 	
	 	 	 	 	






	 		 T2c	 	C10822T		 		
	 	 		 T2c1	 	G6261A	C16292T		 		
	 	 		 		 	T146C!		 		
	 	 		 	 		 T2c1d	 	T279C	C5187T	C7873T		 		
	 	 		 	 	 		 T2c1d1	 	G11914A!		 		
	 	 		 	 	 	 		 T152C	A374G	A5565T	C6644T	G13708A	 		
	 	 		 	 	 	 	 		 C182T	 France	
	 	 		 	 	 	 	 		 T16092C	 France	
	 	 		 	 	 	 	 		 T3645C	 Italy	
	 	 		 T2f	 	C8270T	8281-8289d		 		
	 	 	 		 T2f1	 	T195C!	C6489a		 		
	 	 	 	 		 T2f1a	 	T5277C	T5426C	G15043A	T16298C		 		










































J	 2,7	 0,2	 0,4	 0,1	
non-J	 4,2	 0,2	 0,3	 0,1	




















Family	 Relationship	 Haplogroup	 Private	synonimous	 Private	non	coding	 Provate	tRNA/rRNA	 Private	missense	
1	 Proband	 H1	 	 	 	 6253	T>C/MT-CO1	
2	 Proband	 U2e1		 14470	T>C	 228	G>A	 	 	
3	 Proband	 J1d3a	 11061	C>G		 	 	 14551	A>G/MT-ND6	
4	 Proband	 H26	 5096	T>C	 	 	 	
4	 Maternal	granfather	 R1a1	 7055	A>G		12906	C>T	 	 	 	
5	 Proband	 U2e2a1	 	 16183	A>C	16182	A>C	 	
6249	G>A/MT-CO1	
14790	A>G/MT-CYB	
5	 Father	 H5qa	 	 152	T>C	 	 	
6	 Proband	 H	 7630	T>C	11113	T>C	 	 12172	A>G/MT-TH	 	
7	 Proband	 H1j	 	 	 	 	
8	 Proband	 H70	 	 16192	C>T	16209	T>C	 	 	






10	 Proband	 J1c3	 12477	T>C	12696	T>C	 	 	 	
10	 Father	 H10d		 	 15884	G>A	 729	T>C/MT-RNR1	 10398	A>G/MT-ND3	
11	 Proband	 V	 7804	A>G	 	 3290	T>C/MT-TL1	 	
12	 Proband	 N1b1a	 14097	C>T	14323	G>A	 	 	 	
13	 Proband	 H4a1	 8730	A>G	 	 	 4129	A>G/MT-ND1	7853	G>A/MT-CO2	
14	 Proband	 H3b	 	 	 	 	
15	 Proband	 L3b	 10283	A>G	 	 	 12674	A>G/MT-ND5	
16	 Proband	 T1a1l	 14311	T>C	 	 	 	
16	 Father	 K1b1c	 3918	G>A	13470	A>G	 	 1736	A>G/MT-RNR2	 	
18	 Proband	 J1c3	 	 	 	 	
18	 Father	 H10	 7702	G>A	 	 	 8896	G>C/MT-ATP6	14798	T>C/MT-CYB	
19	 Proband	 J1c8	 3657	C>A	14653	C>T	 	 	 13768	T>C/MT-ND5	







22	 Proband	 H1c2	 	 	 	 	
23	 Proband	 H	 13641	T>C	 	 2648	T>C/MT-RNR2	 	
23	 Father	 H1u	 	 	 1809	T>C/MT-RNR2	 	
24	 Proband	 H20	 9410	A>G	13656	T>C	
16189	T>C	
16192	C>T	 	 	






26	 Proband	 H65	 	 	 	 4491	G>A/MT-ND2	
27	 Proband	 J2b1a2	 11686	C>T	 	 5774	T>C/MT-TC	 	
28	 Proband	 X2m	 6023	G>A		11944	T>C	 	 15910	C>T/MT-TT	 8866	A>G/MT-ATP6	






30	 Proband	 H5a	 3744	A>G	 456	C>T	 	 4659	G>A/MT-ND2	
31	 Proband	 H2b	 4092	G>A	 	 4386	T>C/MT-TQ	 12557	C>T/MT-ND5	

























37	 Proband	 HV0b	 	 16564	A>G	 	 8480	C>T/MT-ATP8	15119	G>A/MT-CYB	
37	 Nephew	 H1	 9932	G>A	11149	G>A	 	 	 	
37	 Nephew	 H	 10232	A>G	16319	T>A	 16319	G>A	 	 	






39	 Proband	 T2b	 11929	T>C	 	 	 	
40	 Proband	 T2a1	 12957	T>C	15265	C>T	 	 	 	






41	 Proband	 U1b2	 6725	C>A	 16042	G>A	 	 	
42	 Proband	 H6a1a	 	 	 5558	A>G/MT-TW	 	
43	 Proband	 N1a3a2	 6743	T>C	 16564	A>G	16565	C>T	 	 	
44	 Proband	 H10a1		 	 16564	A>G	16565	C>T	 2066	C>T/MT-RNR2	 14198	G>A/MT-ND6	
45	 Proband	 H6a1a	 8227	T>C	 	 	 	
46	 Proband	 W1h1	 12927	C>T	 143	G>A	 14727	T>C/MT-TE	 	
47	 Proband	 U5b2a1a1		 14582	A>G	 	 	 	
48	 Proband	 H7	 7340	G>A	 	 	 	
49	 Proband	 H63	 5951	A>G	7094	T>C	 	 	 8701	A>G/MT-ATP6	
51	 Proband	 K1b1c	 	 	 	 	






53	 Proband	 H13a1a2b	 7397	C>T	 200	A>G	 	 4491	G>A/MT-ND2	8701	A>G/MT-ATP6	
54	 Proband	 U5a2	 	 	 	 	






56	 Proband	 T1a1	 9275	A>C	 	 	 8896	G>A/MT-ATP6	13879	T>C/MT-ND5	
57	 Proband	 H1a	 4736	T>C	9374	A>G	 	 	 	
58	 Proband	 H	 15682	A>G	 	 	 3511	A>G/MT-ND1	13889	G>A/MT-ND5	






60	 Proband	 H7		 	 	 	 	







62	 Proband	 H5b	 7861	T>C	14007	A>G	 	 801	A>G/MT-RNR1	 	
62	 Paternal	grandfather	 H6a1b2	 	 	 	 11150	G>A/MT-ND4	
62	 Father	 H5a	 10172	G>A	 	 	 	
63	 Proband	 T2b	 11929	T>C	 	 2903	T>C/MT-RNR2	12172	A>G/MT-TT	 10398	A>G/MT-ND3	
64	 Proband	 U4b1a	 4703	T>C	12609	T>C	 	 	 13708	G>A/MT-ND5	
64	 Father	 T1a1		 14758	A>G	 	 	 	
65	 Proband	 J1b1a2b		 9968	C>T	 	 	 7407	T>C/MT-CO1	
66	 Proband	 V4	 3849	G>A	 	 1657	C>T/MT-TV	 	












68	 Proband	 H1ap	 13194	G>A	 	 2876	G>A/MT-RNR2	 	
69	 Proband	 H13a1a2b	 6959	C>T	 5580	T>C	 	 	
69	 Father	 H	 	 5581	A>T	 	 	
70	 Proband	 I3a1	 13395	A>G	 	 	 	
71	 Proband	 H10aq	 7894	A>G	11314	A>G	
16564	A>G	
16565	A>T	 	 	
















74	 Proband	 U5a2d	 6260	G>A	10984	C>T	 16311	T>C	 	
8887	A>G/MT-ATP6	
12663	C>A/MT-ND5	
74	 Father	 H43	 11149	G>A	 	 	 15773	G>A/MT-CYB	









76	 Proband	 J2b1a5	 3591	G>A	 	 	 7051	T>C/MT-CO1	
77	 Proband	 H18b	 4736	T>C	 16561	A>T	 	 8519	G>A/MT-ATP8	













81	 Proband	 HV4a2	 8763	T>C	14515	T>C	 	 	 	
82	 Proband	 J2a2c		 	 	 15924	A>G/MT-TT	 3508	A>G/MT-ND1	
83	 Proband	 H	 5264	C>T	 	 	 	






85	 Proband	 H	 13431	C>T	 	 	 	




















other	 private	 variants,	 with	 some	 possible	modifying	 or	 pathogenic	 significance.	 For	 each	
variant,	 the	 amino	 acid	 residue	 conservation	 and	 the	 in-silico	 prediction	 values	 of	












PolyPhen2	 SIFT	 PANTHER	 PhD-SNP	 Mammals	 Local	 Global	 -	 +	
m.3316	G>A	 MT-ND1	 p.A4T	 benign	 neutral	 NA	 neutral	 67	 57	 78	 3	 12	
m.3508	A>G	 MT-ND1	 p.I68V	 benign	 neutral	 neutral	 neutral	 27	 67	 78	 5	 7	
m.3511	A>G	 MT-ND1	 p.T69A	 benign	 neutral	 neutral	 neutral	 37	 67	 78	 6	 6	
m.3943	A>G	 MT-ND1	 p.I213V	 benign	 neutral	 neutral	 neutral	 86	 100	 78	 2	 2	
m.4129	A>G	 MT-ND1	 p.T275A	 benign	 neutral	 neutral	 neutral	 89	 81	 78	 1	 3	
m.4491	G>A	 MT-ND2	 p.V8I	 benign	 neutral	 neutral	 neutral	 54	 39	 62	 5	 8	
m.4659	G>A	 MT-ND2	 p.A64T	 benign	 neutral	 disease	 disease	 93	 76	 62	 1	 2	
m.4824	A>G	 MT-ND2	 p.T119A	 benign	 neutral	 disease	 neutral	 94	 81	 62	 1	 1	
m.4917	A>G	 MT-ND2	 p.N150D	 benign	 neutral	 disease	 disease	 93	 43	 62	 15	 11	
m.5194	C>T	 MT-ND2	 p.P242L	 benign	 neutral	 disease	 neutral	 38	 48	 62	 7	 8	
m.6249	G>A	 MT-CO1	 p.A116T	 benign	 neutral	 neutral	 neutral	 83	 100	 95	 1	 3	
m.6253	T>C	 MT-CO1	 p.M117T	 benign	 neutral	 neutral	 neutral	 85	 100	 95	 2	 2	
m.7051	T>C	 MT-CO1	 p.M383T	 probably_damaging	 deleterious	 neutral	 disease	 100	 100	 95	 1	 1	
m.7309	T>C	 MT-CO1	 p.I469T	 benign	 deleterious	 neutral	 disease	 100	 100	 95	 1	 1	
m.7407	T>C	 MT-CO1	 p.Y502H	 benign	 neutral	 neutral	 neutral	 71	 76	 95	 2	 1	
m.7754	G>A	 MT-CO2	 p.D57N	 benign	 neutral	 NA	 disease	 94	 95	 89	 4	 2	
m.7805	G>A	 MT-CO2	 p.V74I	 benign	 neutral	 NA	 neutral	 85	 90	 89	 2	 2	
m.7853	G>A	 MT-CO2	 p.V90I	 benign	 neutral	 neutral	 neutral	 91	 95	 89	 1	 3	
m.8084	A>G	 MT-CO2	 p.T167A	 benign	 neutral	 neutral	 neutral	 91	 100	 89	 1	 2	
m.8480	C>T	 MT-ATP8	 p.P39S	 probably_damaging	 neutral	 neutral	 neutral	 40	 5	 46	 31	 11	
m.8516	T>C	 MT-ATP8	 p.W51R	 probably_damaging	 neutral	 disease	 disease	 100	 48	 46	 42	 4	
m.8519	G>A	 MT-ATP8	 p.E52K	 probably_damaging	 neutral	 disease	 disease	 80	 48	 46	 1	 3	
m.8701	A>G	 MT-ATP6	 p.T59A	 benign	 neutral	 NA	 neutral	 37	 57	 77	 3	 2	
m.8705	T>C	 MT-ATP6	 p.M60T	 benign	 neutral	 NA	 neutral	 61	 57	 77	 4	 1	
m.8833	G>A	 MT-ATP6	 p.A103T	 probably_damaging	 neutral	 disease	 neutral	 68	 90	 77	 5	 1	
m.8866	A>G	 MT-ATP6	 p.I114V	 benign	 neutral	 disease	 neutral	 54	 76	 77	 5	 2	
m.8887	A>G	 MT-ATP6	 p.I121V	 benign	 neutral	 neutral	 neutral	 71	 76	 77	 1	 1	
m.8896	G>A	 MT-ATP6	 p.A124T	 benign	 neutral	 disease	 disease	 78	 81	 77	 2	 1	
m.8896	G>C	 MT-ATP6	 p.A124P	 benign	 neutral	 disease	 disease	 78	 81	 77	 2	 1	
m.8953	A>G	 MT-ATP6	 p.I143V	 probably_damaging	 neutral	 neutral	 neutral	 85	 86	 77	 3	 1	
m.9804	G>A	 MT-CO3	 p.A200T	 benign	 neutral	 neutral	 disease	 93	 95	 92	 2	 1	
m.9957	T>C	 MT-CO3	 p.F251L	 benign	 neutral	 neutral	 disease	 100	 100	 92	 1	 1	
m.10188	A>G	 MT-ND3	 p.M44V	 benign	 neutral	 neutral	 neutral	 81	 86	 69	 2	 3	
m.10398	A>G	 MT-ND3	 p.T114A	 benign	 neutral	 neutral	 neutral	 81	 92	 69	 1	 -	
m.10750	A>G	 MT-ND4L	 p.N94S	 benign	 neutral	 neutral	 disease	 98	 93	 69	 1	 1	
m.11150	G>A	 MT-ND4	 p.A131T	 benign	 deleterious	 NA	 neutral	 82	 95	 77	 2	 2	
m.12557	C>T	 MT-ND5	 p.T74I	 benign	 neutral	 NA	 neutral	 59	 67	 68	 6	 6	
m.12663	C>A	 MT-ND5	 p.N109K	 benign	 neutral	 neutral	 neutral	 72	 86	 68	 1	 2	
m.12674	A>G	 MT-ND5	 p.N113S	 possibly_damaging	 neutral	 disease	 disease	 36	 81	 68	 1	 4	
m.13145	G>A	 MT-ND5	 p.S270N	 benign	 neutral	 neutral	 neutral	 92	 71	 68	 7	 9	
m.13327	A>G	 MT-ND5	 p.T331A	 probably_damaging	 neutral	 disease	 disease	 95	 90	 68	 1	 1	
m.13708	G>A	 MT-ND5	 p.A458T	 benign	 neutral	 disease	 disease	 44	 67	 68	 1	 7	
m.13768	T>C	 MT-ND5	 p.F478L	 benign	 neutral	 disease	 neutral	 77	 48	 68	 4	 3	
m.13879	T>C	 MT-ND5	 p.S515P	 benign	 neutral	 neutral	 neutral	 23	 29	 68	 18	 7	
m.13889	G>A	 MT-ND5	 p.C518Y	 benign	 neutral	 disease	 neutral	 38	 38	 68	 21	 4	
m.14180	T>C	 MT-ND6	 p.Y165C	 probably_damaging	 neutral	 neutral	 disease	 26	 45	 52	 5	 4	
m.14198	G>A	 MT-ND6	 p.T159M	 probably_damaging	 neutral	 neutral	 neutral	 63	 38	 52	 1	 1	
m.14258	G>A	 MT-ND6	 p.P139L	 benign	 neutral	 neutral	 neutral	 37	 38	 52	 57	 2	
m.14279	G>A	 MT-ND6	 p.S132L	 benign	 neutral	 neutral	 neutral	 60	 24	 52	 50	 9	
m.14562	C>T	 MT-ND6	 p.V38I	 benign	 neutral	 neutral	 neutral	 72	 67	 52	 2	 1	
m.14790	A>G	 MT-CYB	 p.N15S	 benign	 neutral	 disease	 disease	 99	 76	 82	 3	 5	
m.14798	T>C	 MT-CYB	 p.F18L	 benign	 neutral	 neutral	 neutral	 89	 81	 82	 6	 2	
m.15119	G>A	 MT-CYB	 p.A125T	 benign	 neutral	 disease	 disease	 99	 86	 82	 1	 1	
m.15773	G>A	 MT-CYB	 p.V343M	 probably_damaging	 neutral	 disease	 disease	 99	 76	 82	 4	 3	
	











As	 a	 first	 step,	 we	 assessed	 the	 possible	 influence	 of	 private	 and	 putative	 pathogenic	
mutations	(Table	10)	disregarding	the	haplogroup	affiliation	on	the	RNFL	thickness	in	OPA1	
patients	 carrying	or	not	 carrying	 such	 variants.	We	 failed	 to	detect	 any	differences	 in	 this	
comparison,	 considering	 the	 average	 RNFL	 thickness	 or	 sector	 by	 sector,	 i.e.	 temporal,	
superior,	nasal,	inferior	(Figures	15,	16).	
	














Next,	 we	 investigated	 the	 variability	 of	 the	 RNFL	 thickness	 according	 to	 the	 different	
haplogroup	affiliation	of	OPA1	patients,	thus	assessing	the	role	of	ancient	mtDNA	variation,	






















p=0.0270),	 thus	 revealing	 a	 putative	 protective	 role	 for	 haplogroup	 U	 and	 damaging	 for	
haplogroup	H	(Uncorrected	Fisher’s	LSD,	p=0.0053)	(Figure	18).	
















is	 the	 main	 target	 of	 the	 neurodegenerative	 process.	 Concerning	 the	 father-children	























respiratory	 chain	 dysfunction,	 somehow	 borderline	 between	 functional	 and	 pathological	
variability,	which	is	certainly	dependent	on	the	presence	of	a	major	predisposing	pathogenic	
mtDNA	 mutation	 (“primary”	 mutation),	 but	 also	 largely	 modulated	 by	 the	 mitogenome	
sequence	 variation	 (mtDNA	haplogroup	with	 “secondary”	 and	private	mutations)	 (Gómez-
Durán	et	al.,	 2010,	2012).	 Furthermore,	 the	 respiratory	defect	and	pathogenic	mechanism	
seem	also	highly	modulated	by	environmental	(Ghelli	et	al.,	2009)	and	nuclear	DNA	factors	
(Carelli	et	al.,	2003).	Thus,	to	date,	by	definition	in	a	LHON	family	it	has	always	been	recognized	





combination	 of	 m.14258G>A/MT-ND6	 and	 m.14582A>G/MT-ND6	 variants	 on	 a	 K1a	
haplogroup	background	(Table	3),	there	was	no	clearly	“primary”	pathogenic	mutation.	Thus,	
the	 only	 variants	 we	 could	 assign	 a	 possible	 pathogenic	 role	 were	 the	missense	 changes	
affecting	the	ND6	subunit	of	complex	I,	here	found	in	a	previously	unreported	combination,	
otherwise	individually	present	in	the	known	public	datasets,	but	on	different	mitogenomes	
(www.mitomap.org).	 On	 the	 clinical	 ground,	 it	 is	 worth	 noting	 that	 all	 affected	members	
(n=14)	 of	 this	 very	 large	 family	 are	males,	 indicating	 that	most	 likely	 the	 combination	 of	
missense	 variants	 on	 the	 K1	 mitogenome	 characterizing	 Families	 1a,	 1b	 and	 1c	 was	 not	
sufficient	 to	 cross	 the	 threshold	 for	 triggering	 LHON	 in	 females.	 Furthermore,	 general	
penetrance	of	these	14	affected	members	was	13%	over	the	total	number	of	individuals	on	










LHON.	 The	 other	 variant	m.10680G>A/MT-ND4L	 found	 in	 Family	 2	 has	 been	 either	 found	
alone	in	pedigrees	segregating	cases	of	LHON	on	the	maternal	line	(Zhang	et	al.,	2012;	Zou	et	
al.,	2010),	or	in	association	with	known	LHON	primary	mutations	(Yang	et	al.,	2009).	Moreover,	
the	mtDNA	 sequence	 variants	 of	 these	 previously	 reported	 cases	 of	 Chinese	 ancestry	 are	
found	in	combination	with	other	missense	changes	in	Complex	I	subunits	genes,	in	particular	
in	 the	ND1	subunit	 (m.3644T>C/MT-ND1;	m.3745G>A/MT-ND1;	m.3548T>C/MT-ND1)	or	 in	
the	ND6	subunit	(m.14484T>C/MT-ND6),	which	are	closely	assembled	with	ND4L	according	to	
the	 currently	 proposed	 Complex	 I	 crystal	 structure	 (Figure	 11,	 Table	 4)	 (Fiedorczuk	 et	 al.,	
2016).	Thus,	at	least	the	m.14258G>A/MT-ND6	(in	the	present	study)	and	m.10680G>A/MT-
ND4L	variants	have	been	recurrently	associated	with	LHON,	either	in	combination	with	other	







respiration	 as	 measured	 by	 OCR	 were	 significantly	 defective	 in	 cybrids	 harboring	 the	
mitogenomes	from	Families	1	and	2	compared	to	haplogroup-matched	controls.	Remarkably,	
similar	to	the	other	LHON	primary	mutations	with	the	exception	of	m.3460G>A/MT-ND1,	the	
Complex	 I	 specific	 activity	 was	 not	 reduced	 in	 cybrids	 carrying	 the	 two	 combinations	 of	
variants	(Carelli	et	al.,	1997,	1999).	Thus,	even	if	other	reports	proposed	that	combinations	of	
different	 variants	might	 exert	 the	 equivalent	 pathogenic	 role	 of	 the	 single	 primary	 LHON	
mutation	(Zhang	et	al.,	2012;	Zou	et	al.,	2010),	we	here	provide	for	the	first	time	experimental	
evidence	of	the	respiratory	chain	impairment	from	a	functional	point	of	view.	Interestingly,	















LHON	 despite	 the	 absence	 of	 the	 three	 common	 LHON	 mutations.	 However,	 also	 the	
sequencing	of	the	entire	mitogenome	in	our	entire	cohort	of	Italian	LHON	families	revealed	









other	 two	 adaptive	 variants	 for	 high	 altitude	 in	 Tibet,	 i.e.	 m.3745G>A/MT-ND1	 and	
m.4216T>C/MT-ND1,	were	also	implicated	in	LHON	(Kang	et	al.,	2013).	The	m.3745G>A/MT-
ND1	was	in	fact	found	in	combination	with	m.10680G>A/MT-ND4L	in	a	Chinese	LHON	Family	
(Yang	 et	 al.,	 2009),	whereas	 the	m.	 4216T>C/MT-ND1	 variant	 is	 at	 the	 shared	 root	 of	 the	




The	 background	 mitogenome	 variability	 may	 be	 associated	 as	 a	 modifying	 factor	 to	 the	
“primary”	mutations	 in	 LHON,	 this	being	particularly	evident	 for	 the	m.14484T>C/MT-ND6	
mutation.	In	fact,	according	to	the	current	literature	the	mitochondrial	haplogroup	J	is	well	
established	to	be	a	modifier	of	penetrance	for	this	mutation,	with	the	strongest	association	








However,	 all	 previous	 studies	 on	 LHON	 cohorts	 did	 not	 analyze	 the	 entire	 sequence	 of	
mitogenomes,	but	only	a	few	SNPs,	which	are	diagnostic	markers	of	haplogrups,	or	at	best	
included	 in	 some	 studies	 the	 sequence	 of	 the	 control	 region,	 with	 only	 a	 few	 pedigrees	
analyzed,	i.e.	6	and	33	respectively	(Carelli	et	al.,	2006;	Hudson	et	al.,	2007).	Thus,	we	decided	
to	collect	all	available	LHON	families	carrying	the	m.14484T>C/MT-ND6	mutation	in	Europe	









study	 found	a	 66.7%	 (4	out	 6)	 of	mutational	 events	on	 J	 haplogroup	 (Carelli	 et	 al.,	 2006).	
Finally,	the	largest	study	ever	by	Hudson	and	colleagues	reported	a	haplogroup	J	frequency	of	
99%	 in	851	 LHON	carrying	m.14484T>C/MT-ND6	mutation,	but	 this	 figure	was	 reached	by	
considering	all	individuals	on	the	33	available	maternal	lineages	(Hudson	et	al.,	2007).		
Furthermore,	the	other	difference	we	have	observed	between	haplogroups	T	and	H	 in	our	
cohort	 may	 be	 due	 to	 the	 reduced	 frequency	 of	 haplogroup	 H,	 as	 counterpart	 of	 the	 J	
predominance,	 or	 to	 a	 milder	 modifier	 role	 of	 haplogruop	 T,	 which	 shares	 the	 common	




A	 side	 result	 of	 our	 sequencing	 analysis	 of	 such	 a	 large	 number	 of	 mitogenomes	 is	 the	
correction	of	previous	haplogroup	affiliation	in	some	families,	which	was	wrong.	The	previous	
analysis	was	carried	out	by	RFLP,	considering	only	a	limited	number	of	diagnostic	variants	for	













In	 2	 independent	 families,	 besides	 the	 primary	 LHON	 m.14484T>C/MT-ND6	 mutation,	 a	
second	 LHON	 “primary”	mutation	was	 found	 (m.3460G>A/MT-ND1	 and	m.11778G>A/MT-
ND4).	 This	 kind	 of	 event,	 though	 rare,	 was	 already	 reported	 in	 one	 family	 with	 both	
m.3460G>A	and	m.11778G>A	and	6	families	with	both	m.14484T>C	and	m.11778G>A	(Brown	
et	al.,	2001;	Catarino	et	al.,	2017;	Cruz-Bermúdez	et	al.,	2016;	Howell	et	al.,	2002;	Riordan-Eva	




proportion	of	 affected	 females,	 impacting	on	 the	male:female	 ratio	 (Catarino	et	 al.,	 2017;	
Howell	et	al.,	2002).	




disorder	 compatible	 with	 the	 definition	 of	 LHON	 “plus”	 (Howell	 et	 al.,	 1991,	 1995).	 The	
sequence	analysis	of	this	family	was	limited	to	the	CI	subunits	genes	only,	and	based	on	the	
reported	 data	 (Howell	 et	 al.,	 1991)	 the	 haplogroup	 affiliation	 of	 this	 Australian	 family	 is	












intragenic	 suppressor,	 ameliorating	 the	 complex	 neurological	 phenotype	 associated	 with	
complex	I	deficiency	(Howell	et	al.,	1991).		









(www.mitomap.org);	moreover,	 the	 same	position,	but	with	a	different	nucleotide	 change	
T>G	causing	a	different	amino	acid	substitution	(p.F293C),	was	found	mutated	in	a	Russian	
LHON	family	carrying	also	the	m.3460G>A/MT-ND1,	on	haplogroup	T1	(Povalko	et	al.,	2005).		




The	 m.4659G>A/MT-ND2	 (p.A64T)	 was	 found	 in	 57	 controls,	 on	 27	 independent	 mtDNA	
backgrounds,	but	never	on	the	haplogroup	J1b1a1d	sub-clade	(www.mitomap.org),	as	in	our	
German	proband.	This	variant	was	postulated	 to	 increase	 the	 risk	of	developing	Parkinson	
disease	(Khusnutdinova	et	al.,	2008),	and	it	also	is	a	marker	of	haplogroup	H2a1n.	
Other	 putative	 “secondary”	 pathogenic	 mutations	 were	 found	 in	 CIV	 and	 CV	 subunits:	
m.6712A>T/MT-CO1,	 m.8516T>C/MT-ATP8,	 m.8989G>A/MT-ATP6,	 m.9025G>A/MT-ATP6	
and	 m.9957T>C/MT-CO3.	 All	 these	 variants	 are	 rare,	 found	 a	 few	 times	 in	 the	 normal	
population	(1,	4,	10,	24,	27,	respectively),	and	never	associated	with	pathologic	phenotypes	
(www.mitomap.org).	 The	 only	 exception	 is	 the	 m.9957T>C/MT-CO3	 variant,	 previously	
associated	 with	 several	 forms	 of	 mitochondrial	 encephalomyopathy:	 mitochondrial	
encephalomyopathy,	lactic	acidosis	and	stroke-like	episodes	(MELAS)	(Manfredi	et	al.,	1995),	






ischemic	 optic	 neuropathy	 (Abu-Amero	 et	 al.,	 2005).	 A	 cell	 study	 on	 cybrids	 carrying	 this	
mutation	showed	a	normal	respiration,	but	increased	ROS	production	(Lenaz	et	al.,	2004).	
The	 putative	 synergistic	 variants	 (m.4824A>G/MT-ND2,	 m.6261G>A/MT-CO1,	
m.7080T>C/MT-CO1,	 m.8557G>C/MT-ATP8,	 m.8812A>G/MT-ATP6,	 m.8953A>G/MT-ATP6,	
m.9055G>A/MT-ATP6)	 were	 found	 in	 57,	 1052,	 253,	 40,	 18,	 46,	 4,	 1769,	 27	 controls,	
respectively.	All	variants	were	not	associated	with	any	neurological	conditions,	except	for	the	
m.6261G>A/MT-CO1	 and	m.9055G>A/MT-ATP6	 variants.	 The	m.6261G>A/MT-CO1	 variant,	
besides	being	found	in	cancer	as	a	somatic	mutation,	was	also	associated	with	a	LHON-like	
optic	neuropathy	in	a	patient	negative	for	primary	LHON	mutations,	on	haplogroup	T2	(Abu-













evolution	and	became	 fixed.	Alternatively,	 the	 LHON	mutational	 events	might	have	arisen	
independently,	 suggesting	 that	 some	 mitogenomes	 could	 predispose	 to	 mutagenesis	 at	
position	m.14484T.	According	 to	Carelli	 and	 colleagues	 (Carelli	 et	 al.,	 2006),	 the	 six	 Italian	
LHON	 families	 originally	 studied	 in	 their	 previous	 report	 carried	 the	m.14484T>C/MT-ND6	
mutation	on	independent	mitochondrial	backgrounds,	thus	the	preferential	association	of	the	
m.14484T>C/MT-ND6	 LHON	 mutation	 with	 haplogroup	 J1	 was	 interpreted	 as	 not	 due	 to	
founder	events	but	to	a	true	mtDNA	background	effect.	It	was	also	proposed	that	the	specific	
combination	of	amino	acid	changes	in	the	cytochrome	b	is	the	possible	cause	of	the	mtDNA	






assembling	 respiratory-chain	 complexes	 I	 and	 III	 (Carelli	 et	 al.,	 2006).	However,	differently	
from	the	Italian	population,	a	clear	major	founder	event	that	might	have	occurred	900–1,800	
years	 ago	 has	 been	 recognized	 in	Northern	 Europe	 (Dutch	 and	 French	 population)	 and	 in	
Canada	 (French-Canadian	 population)	 on	 haplogroup	 J1c1d	 (Howell	 et	 al.,	 2003b).	 The	
association	 of	 m.14484T>C/MT-ND6	 mutation	 with	 haplogroup	 J	 does	 not	 apply	 to	 non-
European	population:	for	example,	a	study	of	an	Indian	LHON	cohort	showed	an	association	
with	 different	 mtDNA	 backgrounds	 (F1c1,	 M31a,	 U2a,	 M*,	 I1,	 M6,	 M3a1,	 and	 R30a),	 as	
independent	mutational	events	(Khan	et	al.,	2013).	
Finally,	on	the	clinical	ground,	penetrance	in	LHON	families	carrying	the	m.14484T>C/MT-ND6	
mutation	 on	 haplogroup	 J	 was	 higher	 than	 those	 on	 non-J	 haplogroups.	 This	 was	 a	 non-
significant	 tendency	 that	 applied	 to	 both	 genders.	 Unfortunately,	 besides	 the	 association	
studies	there	are	no	published	data	on	this	issue,	with	the	actual	calculation	of	penetrance	in	








Hypothetically,	 the	mtDNA	background	may	 be	 also	 a	modifier	 in	DOA	 families	 carrying	 a	
mutation	in	the	OPA1	gene,	considering	the	consolidated	role	of	mitogenome	variability	 in	
LHON	 and	 the	 clinical	 and	 pathophysiological	 similarities	 between	 DOA	 and	 LHON.	 The	
mitochondrial	haplogroups	have	been	already	investigated	in	DOA,	and	these	studies	failed	to	
reveal	 any	 association	 (Han	 et	 al.,	 2006;	 Pierron	 et	 al.,	 2009).	 Our	 results	 confirmed	 this	
finding,	as	expected	for	a	dominantly	inherited	disorder	(Figure	15).	We	used	the	same	mtDNA	
sequencing	approach	 for	DOA	as	 for	 the	m.14484T>C/MT-ND6	LHON	cohort,	and	we	have	
analyzed	 all	 private	 missense	 changes	 to	 detect	 the	 presence	 of	 putative	 pathogenic	
mutations	or	synergistic	variants,	besides	the	normal	population-specific	variability	(Table	10).	
This	analysis	revealed	10	changes	with	a	possible	pathogenic	role.	Most	of	them	are	reported	






















We	thus	 investigated	the	mitogenome	variability	as	a	possible	modifier	 in	 the	DOA	clinical	
outcome,	evaluating	the	haplogroup	association	with	the	RNFL	thickness,	as	evaluated	by	OCT	
and	 reliable	 readout	 of	 disease	 severity.	 First,	 we	 analyzed	 the	 effect	 of	 the	 putative	
pathogenic	 mutations	 and	 synergistic	 variant	 found	 in	 mtDNA.	 These	 mutations	 did	 not	
impinge	on	the	clinical	outcome	of	DOA	patients	(Figures	15,	16).		
Second,	we	evaluated	the	mitogenomes	variability,	fixed	by	evolution	(Figures	16,	17),	finding	
that	 DOA	 patients	 on	 the	 haplogroup	 U	 background	maintain	 a	 significantly	 higher	 RNFL	
thickness	 on	 the	 temporal	 quadrant	 as	 compared	 with	 those	 carrying	 haplogroup	 H.	
Remarkably,	the	specificity	for	the	temporal	fibers,	which	are	the	main	disease	target,	possibly	
indicates	a	real	protective	role.	Noticeably,	haplogroup	H	is	the	most	frequent	in	Europe	and	
often	 found	to	be	more	prevalent	 in	healthy	control	 subjects	 than	 in	patient	study	groups	
(Mueller	 et	 al.,	 2012),	 but	 sometime	was	 also	 associated	 as	 risk	 factor,	 i.e.	 for	 late	 onset	




















mother-child	 (same	mitogenome)	vs	 father-child	 (change	of	 the	mitogenome	haplogroup).	
This	 analysis	 revealed	 that	 the	 mother-children	 segregations	 displayed	 a	 statistically	
significant	 worsening	 of	 the	 clinical	 outcome,	 particularly	 on	 the	 average	 and	 inferior	
quadrant	RNFL	thickness,	with	the	other	quadrants	(temporal,	superior	and	nasal)	presenting	
the	 same	 trend.	 On	 the	 contrary,	 the	 only	 significant	 difference	 in	 the	 father-children	
segregations	was	on	the	temporal	quadrant,	with	a	similar	outcome	on	the	other	quadrants	






the	two	 independent	LHON	families,	were	also	 found	 in	both	LHON	and	DOA	cohorts.	The	
m.14258G>A/MT-ND6	was	found	in	one	proband	of	the	m.14484T>C/MT-ND6	LHON	cohort,	



























with	 the	 clearly	 pathogenic	 mutations,	 as	 in	 the	 case	 of	 the	 LHON	 cohort	 carrying	 the	
m.14258G>A/MT-ND6	mutation.	This	 interaction	seems	to	be	very	strong	also	in	the	LHON	
cohort	 carrying	 the	 primary	 m.14484T>C/MT-ND6	 mutation.	 The	 association	 with	 the	
haplogroup	 J	 root	 highlights	 this	 complex	 interplay,	 revealing	 also	 the	 importance	 of	
geographic	 mitogenome	 stratification	 with	 the	 occurrence	 of	 multiple	 founder	 events	 in	
Europe,	as	well	as	the	possibility	that	certain	mitogenomes	may	predispose	to	mutagenesis,	
which	becomes	eventually	fixed	during	evolution.	























and	 Dr.	 Zeviani,	 Besta	 Institute,	 Milan),	 43	 from	 Germany	 (Prof.	 Wissinger,	 University	 of	
Tubingen;	 Prof.	 Klopstok,	 University	 of	 Munich),	 27	 from	 France	 (Dr.	 Amati	 Bonneau,	




with	 112	 maternally	 unrelated	 patients.	 The	 variants	 are	 described	 according	 to	 OPA1	




Family	 Mutation	 Effect	 Family	 Mutation	 Effect	
1	 c.1334G>A	 p.R445H	 44	 c.1899_90del	 p.E630FfsX2	
2	 c.889C>T	 p.Q297X	 45	 c.2771_2773del	 p.K924del	
3	 c.1212+1G>A	 Splice	defect	 46	 c.2733_2734del	 p.E912GfsX7	
4	 c.1807G>C	 p.D603H	 47	 c.931G>C	 p.A311P	
5	 c.1516+1G>A	 Splice	defect	 48	 c.2825_2828del	 p.V942EfsX25	
6	 c.815T>C	 p.L272P	 49	 c.1212+5G>C	 Splice	defect	
7	 c.2708_2711del	 p.V903GfsX3	 50	 c.1334G>A	 p.R445H	
8	 c.1146A>G	 p.I382M	 51	 c.2713C>T	 p.R905X	
9	 c.1516+1G>A	 Splice	defect	 52	 c.1669C>T	 p.R557X	
10	 c.1516+1G>C	 Splice	Defect	 53	 c.2713C>T	 p.R905X	
11	 c.2708_2711del	 p.V903GfsX3	 54	 c.2215C>T	 p.Q739X	
12	 c.2569C>T	 p.R857X	 55	 c.2825_2828del	 p.V942EfsX25	
13	 c.1724_1725del	 p.E575fsX576	 56	 c.1410_1443+5del	 p.D470fsX	
14	 c.1770G>A	 Exon	Skipping	 57	 c.1346_47insC	 p.T449fsX	
15	 c.2470C>T	 p.R824X	 58	 c.1462A>G	 p.G488R	






17	 c.631_634del	 p.D211KfsX16	 60	 c.2708_2711del	 p.V903GfsX3	
18	 c.2729T>A	 p.V910D	 61	 c.984+3A>T	 Splice	Defect	
19	 c.703C>T	 p.R235X	 62	 c.984+3A>T	 Splice	Defect	
20	 c.2825_2828del	 p.V942EfsX25	 63	 c.2825_2828del	 p.V942EfsX25	
21	 c.2708-2A>T	 Splice	Defect	 64	 c.1334G>A	 p.R445H	
22	 c.2482delG	 p.V828X	 65	 c.2771_2773del	 p.K924del	
23	 c.2819-2A>C	 Exon	Skipping	 66	 c.2726del	 p.N909MfsX58	
24	 c.2341C>T	 p.R781W	 67	 c.869G>A	 p.R290Q	
25	 c.1444-1G>C	 Splice	defect	 68	 c.869G>A	 p.R290Q	
26	 c.2341C>T	 p.R781W	 69	 c.870+5G>A	 Splice	Defect	
27	 c.1196T>A	 p.L399X	 70	 c.2331C>A	 p.Y777X	
28	 c.2708_2711del	 p.V903GfsX3	 71	 c.1484C>T	 p.A495V	
29	 c.893G>A	 p.S298N	 72	 c.113_130del	 p.R38_S43del	
30	 c.2496+1G>A	 Splice	defect	 73	 c.869G>A	 p.R290Q	
31	 c.1609del	 p.H537fs540X	 74	 c.1778T>C	 p.L593P	






34	 c.2131C>T	 p.R711X	 77	 c.2825_2828del	 p.V942EfsX25	
35	 c.1212+3A>T	 Splice	defect	 78	 c.889C>T	 p.Q297X	
36	 c.869G>A	 p.R290Q	 79	 c.2331C>A	 p.Y777X	
37	 c.1462A>G	 p.G488R	 80	 del	exons2-11	 -	
38	 c.2708_2711del	 p.V903GfsX3	 81	 c.703C>T	 p.R235X	
39	 c.751delG	 p.D251MfsX13	 82	 c.784-21_784-
22InsAluYb8	
Exon	Skipping	
40	 c.1587del	 p.L529fs534X	 83	 c.1316G>T	 p.G439V	
41	 c.869G>A	 p.R290Q	 84	 c.1187T>G	 p.L396P	
42	 c.869G>A	 p.R290Q	 85	 c.2815del	 p.L939Sfs28	
43	 del	exon19	 -	 	 	 	
Table	11.	OPA1	mutation		
The	RNFL	(retinal	nerve	fibers	layer)	thickness	was	evaluated	in	91	patients,	from	49	families,	
by	 the	 Stratus	 OCT	 (Optical	 Coherent	 Tomography),	 at	 Prof.	 Valerio	 Carelli’s	
Neurophthamology	Clinic	(IRCCS	Institute	of	Neurological	Science,	University	of	Bologna)	and	
Dr.	Piero	Barboni’s	clinic	(Studio	Oculistico	d'Azeglio,	Bologna).	Data	are	shown	in	Table	12.	
Family	 Relationship	 OD	 OS	AVG	 T		 S	 N	 I	 AVG	 T	 S	 N	 I	
3	 Proband	 52	 38	 77	 48	 46	 48	 29	 73	 45	 43	
4	 Brother	 64	 33	 66	 71	 85	 43	 36	 53	 41	 43	
4	 Maternal	granfather	 75	 35	 93	 77	 95	 83	 35	 98	 96	 105	
4	 Mother	 87	 38	 123	 63	 123	 95	 35	 142	 73	 128	
4	 Proband	 46	 33	 71	 33	 48	 55	 26	 80	 48	 67	
5	 Father	 55	 35	 71	 46	 67	 49	 24	 74	 40	 50	
5	 Proband	 66	 30	 100	 58	 75	 65	 34	 87	 60	 79	
7	 Proband	 59	 26	 92	 55	 61	 64	 28	 95	 61	 71	
8	 Father	 84	 77	 102	 51	 106	 87	 57	 118	 64	 111	
8	 Proband	 89	 44	 101	 98	 116	 85	 42	 106	 82	 109	
10	 Proband	 73	 27	 106	 75	 84	 70	 34	 109	 60	 78	
12	 Proband	 62	 32	 88	 57	 71	 59	 31	 90	 51	 63	
13	 Sister	 100	 64	 130	 79	 125	 73	 26	 89	 53	 122	






18	 Father	 56	 34	 65	 51	 74	 62	 35	 85	 47	 80	
18	 Proband	 68	 39	 83	 56	 95	 71	 35	 113	 47	 88	
18	 Paternal	aunt	 59	 38	 88	 51	 61	 60	 36	 88	 55	 63	
19	 Proband	 59	 32	 86	 60	 60	 60	 60	 91	 31	 59	
22	 Brother	 98	 49	 131	 97	 114	 115	 61	 146	 118	 134	
22	 Mother	 85	 45	 122	 79	 92	 91	 45	 120	 103	 95	
22	 Maternal	Granmother	 89	 76	 90	 61	 131	 75	 55	 95	 55	 96	
22	 Proband	 71	 26	 123	 67	 67	 73	 27	 131	 63	 70	
23	 Father	 66	 40	 94	 64	 68	 65	 31	 85	 56	 90	
23	 Proband	 82	 34	 105	 99	 90	 73	 26	 102	 81	 82	
23	 Sister	 65	 36	 94	 68	 64	 64	 34	 88	 60	 73	
26	 Mother	 92	 81	 115	 64	 110	 95	 71	 133	 62	 116	
26	 Proband	 59	 26	 100	 50	 59	 62	 34	 107	 47	 62	
27	 Proband	 67	 30	 91	 67	 78	 74	 40	 95	 69	 93	
27	 Sister	 78	 49	 106	 64	 94	 77	 42	 103	 71	 91	
28	 Father	 76	 45	 101	 62	 97	 86	 52	 103	 91	 97	
28	 Proband	 73	 51	 101	 59	 82	 69	 52	 73	 56	 95	
29	 Proband	 46	 34	 59	 33	 59	 40	 42	 42	 27	 50	
30	 Proband	 93	 43	 125	 94	 110	 93	 34	 134	 94	 111	
32	 Mother	 57	 38	 76	 54	 61	 74	 68	 77	 98	 55	
32	 Proband	 61	 29	 88	 65	 61	 62	 41	 87	 60	 59	
32	 Proband	 61	 48	 76	 56	 64	 58	 42	 79	 59	 54	
32	 Maternal	aunt	 65	 25	 99	 61	 76	 67	 31	 102	 57	 80	
35	 Father	 63	 36	 86	 54	 75	 58	 33	 84	 51	 62	
35	 Proband	 57	 28	 95	 49	 57	 54	 31	 83	 46	 57	
36	 Proband	 52	 45	 60	 45	 59	 42	 29	 47	 35	 55	
37	 Nephew	 58	 27	 83	 49	 73	 59	 33	 91	 41	 69	
37	 Nephew	 103	 68	 128	 93	 124	 106	 71	 122	 105	 127	
37	 Proband	 69	 48	 81	 60	 88	 65	 45	 83	 47	 86	
38	 Daughter	 49	 27	 69	 50	 51	 57	 32	 81	 63	 52	
38	 Proband	 62	 30	 87	 63	 69	 60	 28	 99	 49	 62	
39	 Sister	 60	 31	 84	 53	 71	 54	 30	 82	 39	 64	
40	 Son	 72	 47	 89	 61	 95	 72	 54	 90	 57	 89	
40	 Proband	 48	 23	 72	 47	 48	 49	 27	 75	 42	 51	
45	 Proband	 69	 54	 86	 58	 79	 73	 53	 92	 48	 98	
48	 Mother	 68	 29	 90	 74	 80	 70	 31	 93	 67	 89	
48	 Proband	 54	 27	 71	 63	 56	 60	 38	 82	 59	 61	
52	 Proband	 66	 35	 101	 50	 80	 72	 32	 112	 68	 79	
54	 Brother	 75	 28	 118	 79	 74	 82	 34	 92	 99	 102	
54	 Cousin	 63	 46	 102	 55	 49	 50	 27	 76	 45	 53	
54	 Proband	 80	 41	 105	 77	 95	 92	 73	 112	 66	 118	
55	 Proband	 74	 57	 85	 70	 83	 61	 38	 88	 60	 57	
57	 Mother	 78	 33	 104	 64	 112	 82	 29	 114	 64	 123	
57	 Proband	 53	 26	 94	 43	 50	 61	 34	 106	 48	 56	
57	 Sister	 74	 40	 112	 69	 77	 70	 34	 108	 45	 91	
60	 Father	 83	 43	 106	 81	 102	 82	 44	 126	 63	 96	
60	 Proband	 66	 29	 80	 74	 82	 67	 29	 88	 73	 79	
61	 Brother	 54	 47	 42	 49	 77	 56	 44	 76	 43	 60	
61	 Mother	 60	 31	 80	 60	 68	 56	 35	 69	 55	 63	
61	 Proband	 54	 41	 64	 42	 71	 na	 na	 na	 na	 na	
62	 Father	 61	 38	 89	 51	 67	 55	 25	 77	 50	 68	
62	 Paterna	granfather	 46	 28	 53	 50	 53	 51	 35	 71	 51	 49	
62	 Proband	 56	 27	 80	 48	 70	 55	 24	 91	 48	 58	






64	 Father	 43	 36	 45	 38	 52	 48	 32	 62	 48	 48	
64	 Proband	 59	 57	 56	 41	 83	 63	 39	 75	 52	 86	
66	 Father	 na	 na	 na	 na	 na	 66	 42	 111	 46	 63	
66	 Proband	 41	 26	 68	 34	 36	 46	 27	 69	 39	 49	
68	 Mother	 50	 47	 63	 34	 55	 42	 37	 56	 27	 47	
68	 Proband	 50	 35	 70	 39	 58	 50	 30	 63	 43	 65	
68	 Sister	 59	 33	 89	 44	 69	 63	 44	 91	 53	 65	
69	 Proband	 70	 34	 108	 66	 72	 71	 35	 95	 69	 87	
70	 Mother	 62	 26	 84	 62	 77	 60	 28	 78	 59	 74	
70	 Proband	 66	 38	 100	 61	 66	 56	 34	 87	 41	 63	
72	 Paternal	aunt	 84	 55	 108	 54	 120	 86	 58	 109	 50	 127	
73	 Proband	 59	 33	 64	 47	 93	 53	 30	 65	 36	 79	
74	 Proband	 44	 36	 63	 38	 38	 42	 31	 55	 39	 45	
74	 Sister	 39	 30	 54	 29	 41	 43	 31	 54	 39	 47	
75	 Proband	 78	 29	 123	 79	 81	 80	 42	 121	 66	 94	
78	 Brother	 62	 41	 87	 59	 60	 60	 36	 87	 53	 63	
78	 Proband	 57	 35	 76	 50	 66	 63	 34	 78	 61	 80	
79	 Proband	 76	 46	 94	 57	 94	 61	 39	 86	 47	 72	
81	 Proband	 65	 33	 89	 62	 74	 59	 38	 65	 64	 70	
82	 Proband	 51	 28	 74	 42	 58	 50	 33	 86	 36	 46	
83	 Father	 51	 59	 44	 33	 68	 na	 na	 na	 na	 na	
83	 Proband	 44	 38	 44	 44	 48	 na	 na	 na	 na	 na	





Direct	 sequence	 analysis	 of	 the	 entire	mtDNA	molecule	was	 performed	 on	 total	 DNA,	 by	
Sanger	(Torroni	et	al.,	2001).	The	protocol	consists	in	11	amplicons	(Table	13).	The	PCR	mixture	
contained	50	ng	of	DNA,	0.5U	GoTaq®	G2	Flexi	DNA	Polymerase	5U/µl	(Promega),	1x	Colorless	





Primer	 Position	(mtDNA)	 Sequence	(5’	→3’)	 Length	product	(bp)	
1F	 14900	 149191	 GCCATGCACTACTCACCAGA	 1760	
1R	 90	 71	 AATGCTATCGCGTGCATACC	
2F	 16458	 16477	 CCCATAACACTTGGGGGTAG	 1682	
2R	 1570	 1549	 TGTAAGTTGGGTGCTTTGTGTT	
3F	 1404	 1425	 ACTTAAGGGTCGAAGGTGGATT	 1832	
3R	 3235	 3214	 CTTAACAAACCCTGTTCTTGGG	
4F	 2932	 2951	 GGGATAACAGCGCAATCCTA	 1607	
4R	 4538	 4519	 GCTTAGCGCTGTGATGAGTG	
5F	 4366	 4387	 AAAATTCTCCGTGCCACCTATC	 1659	






6F	 5871	 5892	 GCTTCACTCAGCCATTTTACCT	 1747	
6R	 7617	 7596	 TCTTGTAGACCTACTTGCGCTG	
7F	 7356	 7379	 GTAGAAGAACCCTCCATAAACCTG	 1822	
7R	 9177	 9154	 TAGAAGTGTGAAAACGTAGGCTTG	
8F	 8896	 8914	 GCCCTAGCCCACTTCTTACC	 1740	
8R	 10728	 10708	 GGCCATATGTGTTGGAGATTG	
9F	 10466	 10485	 CCAAATGCCCCTCATTTACA	 1774	
9R	 12240	 12221	 GGGGCATGAGTTAGCAGTTC	
10F	 12014	 12035	 CTCACCCACCACATTAACAACA	 1816	
10R	 13829	 13808	 AGTCCTAGGAAAGTGACAGCGA	
11F	 13504	 13525	 TACTCCAAAGACCACATCATCG	 1804	







The	 sequencing	 reaction	 mixture	 contained	 100-200	 ng	 of	 DNA	 template,	 0.5%	 DMSO	






1	 14948	 14967	 CACATCACTCGAGACGTAAA	
1	 15564	 15583	 ATTTCCTATTCGCCTACACA	
1	 58	 39	 AATACCAAATGCATGGAGAG	
2	 16522	 16541	 TAAAGCCTAAATAGCCCACA	
2	 584	 603	 TAGCTTACCTCCTCAAAGCA	
2	 1060	 1079	 AAGACCCAAACTGGGATTAG	
3	 1445	 1464	 GAGTGCTTAGTTGAACAGGG	
3	 2047	 2066	 TTTAAATTTGCCCACAGAAC	
3	 2509	 2528	 ATCACCTCTAGCATCACCAG	
4	 3067	 3088	 TGAGTTCAGACCGGAGTAAT	
4	 3540	 3561	 TCTCACCATCGCTCTTCTAC	
4	 4010	 4029	 ACACCCTCACCACTACAATC	
5	 4410	 4429	 CAGCTAAATAAGCTATCGGG	
5	 5014	 5033	 CCTCAATTACCCACATAGGA	
5	 5544	 5563	 TCAAAGCCCTCAGTAAGTTG	
6	 6041	 6060	 CCTTCTAGGTAACGACCACA	
6	 6473	 6492	 CACAGCAGTCCTACTTCTCC	






7	 7416	 7435	 TTCGAAGAACCCGTATACAT	
7	 7987	 8006	 ACTCCTTGACGTTGACAATC	
7	 8505	 8524	 ATAACAAACCCTGAGAACCA	
8	 8975	 8992	 TCATTCAACCAATAGCCC	
8	 9589	 9608	 AAGTCCCACTCCTAAACACA	
8	 10147	 10166	 ACATAGAAAAATCCACCCCT	
9	 10498	 10519	 TAGCATTTACCATCTCACTTCT	
9	 11081	 11100	 ATAACATTCACAGCCACAGA	
9	 11644	 11663	 CCTCGTAGTAACAGCCATTC	
10	 12114	 12132	 ACATCATTACCGGGTTTTC	
10	 12611	 12630	 ATTCATCCCTGTAGCATTGT	
10	 13134	 13153	 AGCAGAAAATAGCCCACTAA	
11	 13596	 13615	 CGCCTATAGCACTCGAATAA	
11	 14115	 14134	 CCCACTCATCCTAACCCTAC	
11	 14646	 14665	 CACTCAACAGAAACAAAGCA	
Table	14.	Primer	list	for	mitochondrial	genome	sequencing	
	













Primer	 Position	(mtDNA)	 Sequence	(5’-3’)	 Length	product	(	bp)	
MTL-F1	 9397	 9416	 AAAGCACATACCAAGGCCAC	 9064	
MTL-R1	 1892	 1873	 TTGGCTCTCCTTGCAAAGTT	
MTL-F2	 15195	 15214	 TATCCGCCATCCCATACATT	 11170	













CA).	 After	 fluorimetric	 quantification,	 using	Quantus	 Fluorometer	with	Quantifluor	 dsDNA	
System	(Pomega),	the	target	DNA	were	diluted	to	the	final	concentration	of	0,4	ng	µL.	The	
first	 step	 is	 tagmentation	 reaction,	 using	 “NexteraXT	 Transposome”,	which	 fragment	DNA	
adding	simultaneously	DNA	adapters	ends.	The	reaction,	in	a	final	volume	of	20	µl,	contains	2	
ng	of	DNA,	10	µl	TD	(Tagment	DNA	Buffer),	5	µl	of	ATM	(Amplicon	Tagment	Mix),	incubated	
at	 55°C	 for	 5	 min,	 and	 immediately	 added	 5	 µl	 of	 NT	 (Neutralize	 Tagment	 Buffer)	 and	
incubated	at	25°C	for	5	min.	






The	 PCR	 product	 were	 purified	 using	 magnetic	 beads,	 AMPure	 XP	 (Beckman-Coulter),	






















Sequence	output	given	 from	sequencer	 is	a	 file	 in	FASTAQ	format,	where	each	base	call	 is	
associated	to	a	“quality	score”.	Through	 instrument	software	 (MiSeq	Reporter),	 sequences	
are	 aligned	 to	 the	 mitochondrial	 genome	 reference	 sequence,	 rCRS	 (	 revised	 Cambridge	
Reference	 Sequence),	 creating	 the	 alignment	 file	 (BAM)	 and	 identifying	 also	 sequences	
variants	(	variant	calling),	listing	in	a	VCF	file	(	Variant	Call	File).	
Population	frequencies	of	missense	mutations	and	the	mtDNA	backgrounds	on	which	they	
were	 observed	 were	 recovered	 from	 two	 public	 databases,	 Mitomap	
(http://www.mitomap.org)	 and	 HmtDB	 (http://www.hmtdb.uniba.it)	 (Lott	 et	 al.,	 2013;	





silico	 protocol	 (Polyphen2,	 SIFT,	 FatHmm,	 PROVEAN,	 MutationAssessor,	 CADD,	 PANTHER,	
PhD-SNP,	 MtoolBox,	 APOGEE_boost)	 (Achilli	 et	 al.,	 2012),	 available	 on	 MitImpact	 2.7	



















(FasL	 gene)	 were	 co-amplified	 by	 multiplex	 polymerase	 chain	 reaction	 according	 to	 the	
primers,	 probes	 and	 conditions	 previously	 published	 (Cossarizza	 et	 al.,	 2003).	 These	 two	
fragments	were	cloned	tale	to	tale	in	a	vector	and	serial	dilutions	were	used	to	construct	a	





analysis,	 including	 cytochrome	 c	 oxidase	 (COX)	 and	 succinic	 dehydrogenase	 (SDH)	 activity	
staining,	were	performed	 (Dubowitz	et	al.,	 2013).	Respiratory	 chain	 complexes	and	citrate	
synthase	(CS)	redox	enzymatic	activities	were	determined	on	skeletal	muscle	homogenates	as	





DB,	 0.3	mM	KCN	and	200	μM	NADH	 (Janssen	 et	 al.,	 2007),	 after	 the	 subtraction	of	 1	 µM	






activity	 was	 determined	 adding	 60	 μM	 of	 reduced	 bovine	 heart	 cytochrome	 c,	 after	
subtraction	 of	 0.3	 mM	 KCN-insensitive	 activity.	 Data	 were	 corrected	 for	 citrate	 synthase	
activity	 (Trounce	et	al.,	1996)	and	protein	content	measured	with	Bradford	assay.	Skeletal	











Cybrid	 cell	 lines	 were	 generated	 in	 Dr.	 Monica	 Montopoli’s	 Laboratory	 (Department	 of	





















basal	 conditions	 and	 after	 the	 sequential	 addition	 of	 1μM	 oligomycin,	 0.2	 μM	 FCCP	



































Hydrogen	 peroxide	 was	 determined	 after	 incubation	 with	 5	 μM	 of	 2,7-
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